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ABSTRACT 
Long-term consumption of soy or red wine has been shown to protect against 
cardiovascular disease. Japanese and French, who consume large amount of soy 
products or red wine, are less prone to cardiovascular disease. Dietary 
phytoestrogens are believed to be the contributing factor. Epidemiological and 
animal studies have demonstrated the hypocholesterolemic effect of the compounds. 
Monkeys fed with soy protein with isoflavones have less atherosclerogenic potential 
than those consumed isoflavone-depleted soy, with increases in hepatic low-density 
lipoprotein receptor (LDLR) and serum high-density lipoprotein (HDL) expression 
in the isoflavone-consuming group. Red wine polyphenols have been shown to 
increase LDLR activity in HepG2 cells and HDL production in rats. 
Hepatic LDLR is a surface glycoprotein which plays a very important role in 
clearance of excess plasma cholesterol. Apolipoprotein Al (APOAl), as a major 
component in HDL, helps to circulate excess serum cholesterol back to liver. How 
phytoestrogens regulate these two genes is still controversial. Their structural 
similarities with estrogen may have given a clue. In this study, the soy isoflavones 
(genistein, daidzein and its respective metabolite equol) and resveratrol from red 
wine were investigated using HepG2 cells as a study model. Their mechanism of 
regulation of the two genes was studied and responsive regions on promoters were 
identified. 
All phytoestrogens studied were able to up-regulate the transcription of LDLR 
promoter in a dose dependent manner. Estrogen receptor a (ERa) but not its isoform 
ERp was shown to be involved in the regulation by isoflavones. Regulation by 
resveratrol was independent on neither form o f receptors. Pre-treatment with 
mitogen-activated protein kinase (MARK) inhibitor, protein kinase A (PKA) 
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inhibitor or protein kinase C (PKC) inhibitor failed to inhibit the isoflavones-induced 
p,omoter transcription activities. PKC inhibitor pre-treatment significant reduced 
resveratrol-induced activity in the absence of ERa, but those of PKA and MAPK 
showed no inhibition. 
Response region on LDLR promoter in the regulation by isoflavones was 
identified in -202 to -127, while that by resveratrol was located at region -447 
to -127. 一 2 0 2 to -127 is the region where the three repeats R l , R2 and R3 are 
located. Point mutation on these repeats all resulted in decreased transcription 
activities, but the s t a t i on on R3 showed the most significant reduction, in both 
cases ofisoflavones and resveratrol. Expression of related transcription factors was 
examined. Sterol regulatory element binding protein -1 (SREBP-l) expression was 
slightly up-regulated upon isoflavone treatment, while that of SREBP-2 was only 
up-regulated by genistein and resveratrol. Expression ofSpl was not affected. 
Both transcriptional activity and mRNA expression of APOAI were 
up-regulated by isotlavones and resveratrol in the presence of ERa but not ERP. The 
up-regulated transcription activities were totally abolished when the cells were 
p,-e-treated with estrogen antagonist 丨CI 182,780. Pre-treatment of MAPK inhibitor, 
PKA inhibitor or PKC inhibitor failed to inhibit the phytoestrogen-induced 
transcriptional activities. 
Response region on APOAI promoter in the regulation by phytoestrogens were 
identified.丨RCE was one of the possible response elements upon genistein treatment, 
while element A might play a role in cells treated with daidzein or equol. Two 
regions, which located at -403 to -243 and -118 to -40，had been identified to be 
involved in the regulations. In these two regions, two Spl binding sites were located. 
in conclusion, the results obtained suggested that soy isoflavones and 

























列之中’而白藜蘆醇調控中的則位於 - 4 4 7至 - 2 0 2及 - 2 0 2至 - 1 2 7的序列之 
中。-202至-127就是三個重複序列（Rl, R2及R3 )的所在之處 °不論是異黃 
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酮或白藜蘆醇的調控中，點突變於三個重複序列之其一上均能引致啓動子轉錄 
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CHAPTER 1 GENERAL INTRODUCTION 
Cardiovascular diseases (CVD) have been one of the leading causes of death in 
the world, with 16.7 million deaths each year. In Hong Kong, diseases of the heart 
causes the second highest death rate from 1981 to 2002 (Department of Health, 
2005). Although CVD is so alarming, some populations like Japanese and French 
people, are less prone to the diseases (American Heart Association, 2005). Among 
many possible reasons, diets have been shown to be a factor. 
Epidemiologic studies support the cardioprotective effect of soy consumption. 
Japanese men who consume large amounts of soy have approximately one-six the 
risk of coronary heart disease as their counterparts in America (Beaglehole, 1990). 
Another study has also illustrated the association between soy product intake and 
heart disease in Japan (Nagata, 2000). 
Red wine drinking has been suspected to account for the low CVD mortality 
rate of French people despite the high amount of saturated fat in their diet. This has 
been known as the "French paradox" phenomenon (Criqiii and Ringel, 1994). 
Epidemiological studies have suggested that consuming red wine at a level 
comparable to that of France could reduce the risk of arteriosclerosis (Renaud and de 
Lorgeril, 1992). 
The active cardioprotective components in these foods are still controversial. 
Scientists have suggested the active ingredients are soybean protein and alcohol in 
red wine, while others have suspected phytoestrogens. 
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L I ROLE OF PHYTOESTROGENS IN SOY AND RED WINE IN 
THE PREVENTION OF CARDIOVASCULAR DISEASES 
1.1.1 INTRODUCTION AND CLASSIFICATION OF PHYTOESTROGENS 
Phytoestrogens are plant-derived chemicals which are structurally similar to 
mammalian estrogen 17p-estradiol (E2) (Price and Fenwick, 1985; Knight and Eden, 
1996; Mazur, 1998). The aromatic ring and the hydroxy! group of phytoestrogens are 
important for binding effectiveness to estrogen receptors (ER) and the remainder of 
the ER will accept hydrophobic groups (Anstead et al., 1997). As estrogen agonists, 
they can mimic the effect of endogenous estrogens, while they may also act as 
antagonists by blocking or altering ER and abolish estrogenic activity (Brzezinski 
and Debi, 1999). They are considered to play an important role in the prevention of 
cancers, heart disease, menopausal symptoms and osteoporosis (Setchell, 1998; 
Adlercreutz, 2002; Kronen berg and Fugh-Berman, 2002). 
They can be classified according to their differences in structure and functional 
group as shown in Figure 1.1 (Cos et al., 2003). The most commonly found groups 
of phytoestrogens are isoflavones (Kingsbury, 1969), coumestans (Bickoff et al., 
1957), liganas (Setcheil et al” 1980), chalcones (Rafi et al., 2000), flavones 
(Milligan et al., 1999), saponins (Chan et a l , 2002) and so on. 
In this study, four phytoestrogens were investigated. Three of them were 
genistein (4',5,7-trihydroxyisoflavone), daidzein (4,,7-dihydroxyisoflavone) and 
equol (7-hydroxy-3-(4'-hydroxyphenyl)-chroman), which are classified as 
isoflavones and mainly found in clover (Adams, 1995), soy and related products 
(Reinli and Block, 1996; Fraiike et al., 1998). Being found as glycosides in plants 
(Ibarreta et al., 2001), they are readily degraded by gut enzymes to form aglycones 
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(Price and Fenvvick, 1985) and absorbed to the bloodstream. Another tested 
phytoestrogen was resveratrol (trans-3,4',5-trihydroxysilbene), which is a stilbene 
and solely extracted from red wine and grape skin (Goldberg et al., 1995; 
Kiraly-Veghely et al., 1998). Their structures are shown in Figure 1.2. 
1.1.2 ESTROGENICITY OF PHYTOESTROGENS AND ABUNDANCES【N 
PLASMA 
Based on their binding affinities to ER, the estrogenic activities of 
phytoestrogens are around 1/500 to 1/1000 of that of estrogen (Jefferson et al., 2002; 
JoLing et al., 2003). Due to the slight structural differences, they have various degrees 
of binding affinities towards different isoforms of ER. Among the soy isoflavones, 
genistein exerts the greatest binding affinitiy to ERa, and daidzein binds weaker to 
both isoforms of ER than its metabolite equol (Setchell et al., 1984; Latonnelle et al., 
2002). However, equol has shown a greater binding affinity to ERp than genistein, 
while resveratrol displays the lowest ER binding affinity in both isoforms (Mueller et 
al., 2004). Isoflavones are usually considered as ER agonists (Mueller et al., 2004) 
but resveratrol can either be agonist or antagonist (Bowers et al., 2000). 
Although phytoestrogens have less potent estrogenic activities than estrogen, 
plasma concentrations of some populations can be lOOO-foid higher than that of 
estrogen. Therefore they could alter physiological metabolism comparable to 
estrogen. For example, middle-aged Japanese' sera contains on the average 
492.7nmol/L of genistein, 282.5nmol/L of daidzein and 99.1niTiol/L of equol 
(Morton et al., 2002). Relatively speaking, the bioavailability of resveratrol is low. 
An intake of 25mg of it, which can be extracted from 5L of red wine, results only 
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Figure 1.2 Structures of 17p-estradiol and phytoestrogens in this study. 
A: 17p-estradiol; A: genistein; B: daidzein; C: equol; D: resveratrol 
20 
1.1.3 PHYTOESTROGENS AS ONE OF THE ACTIVE COMPONENTS IN 
C V D PROTECTION 
Numerous studies have investigated about the underlying mechanisms of the 
cardioprotective effect of soy isoflavones and red wine polyphoenols. Proposed 
mechanisms include anti-LDL oxidation, endothelium-mediated vasodilation, 
inhibition of the expression of tissue factor and reduction of platelet aggregation 
(Clarkson, 2002; Kris-Etherton etal., 2002). 
Modulation of plasma cholesterol is another possible mechanism for 
isoflavones. In two meta-analysis, reduction of plasma LDL cholesterol and 
triglycerides, as well as increased HDL cholesterol have been illustrated (Anderson 
et al.，1995; Zhan and Ho, 2005). Most studies on rats have shown a decrease in total 
plasma cholesterol and LDL cholesterol in the group consuming soy isoflavones 
(Demonty et al., 2003). Similar findings have also been shown in studies carried out 
in rhesus monkeys (Anthony et al., 1996; Anthony et al., 1997). Genistein has also 
been shown to reduce serum cholesterol in ovariectomized rats (Nogowski et al., 
1998). However, on the other hand, isoflavones-containing soy has not demonstrated 
any specific effect on blood lipid profile in some other studies. A meta-analysis of 10 
epidemiological studies found out that consumption of soy-associated isoflavones is 
not related to changes in LDL or HDL cholesterol (Weggemans and Trautwein, 
2003). 
Concerning red wine polyphenols, the major focus of research is about its 
antioxidant property (Wu et al., 2001), fewer studies have been carried out to 
investigate the effect on plasma cholesterol in animal or cell culture. Total 
cholesterol reduction has been observed in hypercholesterolemic golden Syrian 
hamsters force-fed with red wine phenolic extract, which is dissolved in ethanol or 
water. (Auger et al., 2002). A study conducted in healthy and hypercholesterolemic 
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rats has shown that total cholesterol is reduced upon resveratrol and flavonoid 
treatment (Kollar et al., 2000). 
1.1.4 EFFECTS OF PHYTOESTROGENS ON L D L RECEPTOR AND 
APOLJPOPROTEIN A-I 
Serum LDL-cholesterol and HDL-cholesterol can be regulated by LDL receptor 
and apolipoprotein A-I respectively (Cortese et al., 1983; Zabalawi et al., 2003). 
Some studies have investigated the relationship between phytoestrogens and these 
two genes. 
Hypocholesterolemic postmenopausal women who receive soy-isoflavones 
containing diets for 14 days display an increase in mononuclear cell LDL receptors 
mRNA (Baum et al., 1998). Dietary isoflavones reduce plasma cholesterol and 
atherosclerosis in C57BL/6 mice but not LDL receptor-deficient mice, indicating 
that the cholesterol lowering effect may be exerted via LDL receptor (Kirk et al., 
1998). In HepG2 cells, administration of isoflavonoids, formononetin, biochanin A 
and daidzein, results in significant elevations in LDL receptor activity at 
pharmacological concentrations above 40 uM. Coumestrol causes a 3-fold increase 
in receptor activity at a concentration of 50 uM while enterolactone significantly . 
upregulates LDL receptor activity at 50 uM (Owen et al., 2004). Red wine 
polyphenols increase expression of LDL receptor and suppress secretion of 
apolipoprotein B-lOO as demostrated in a cell culture study (Pal et al., 2003). 
Soy protein with intact isoflavones has shown to increase serum HDL 
concentration (Sanders et al” 2002) but little attentions have been paid on the 
relation between phytoestrogens and apolipoprotein A-I. Up till now, the major 
focus is only on genistein, Lamon-Fava S. and co-workers (2000; 2004) have 
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demonstrated that genistein activated apolipoprotein A-I gene expression in HepG2, 
similar to that of estrogen. 
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1.2 ROLE OF ESTROGEN RECEPTORS IN GENE REGULATION 
1.2.1 STRUCTURE, CLASSIFICATION AND TISSUE DISTRIBUTION OF E R S 
Estrogen receptor is a ligand-dependent nuclear receptor that participates in 
transcriptional regulation. Before being activated, ER is associated in a protein 
complex containing heat-shoch protein 90, which prevents the association of the 
receptor with DNA. Activation of ER can be achieved by ligands or other 
ligand-independent way. A confrimational change of the receptor is resulted when it 
is activated. The receptor dissociate the protein complex, it is then phosphorylated 
and binds to its DNA response element and imitates gene transcription (Parker et al., 
1993). 
The receptor generally contains six domains from N- to C-terminus. Three of 
them are the major functional domains: an activation Function-1 (AF-I) located at 
the N-terininus, a DNA Binding Domain (DBD) and a Ligand Binding Domain 
(LBD). LBD modulates transcription in a gene- and cell- specific manner. DBD 
have two functionally distinct zinc fingers which allow ER interacting directly with 
the DNA helix, while LBD contains Activation Function-2 (AF-2) which is the site 
for ligand binding (Klinge, 2001). Both the AF-1 and AF-2 domains of ERa are 
shown to have transcriptional activation functions (Tora et al., 1989), and interact 
with transcriptional mediators and co-factors (Endoh et al., 1999; Rachez et al., 1999; 
Fernandes et al., 2003). More than 80% of ERa is shown to localize in the nucleus in 
the absence of estrogen, and more than 95% is shown to localize in the nucleus upon 
estrogen stimulation (Ylikomi et al., 1992). Thus, it has been believed that the action 
of estrogen is mediated by nuclear-localizing ER through the regulation of target 
gene transcription. 
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There are two isoforms of ER identified. They are known as ERa and ERp 
(Kong et al.，2003). A comparison of the two isoforms is shown in Fig. 1.3. Although 
their three-dimensional arrangement is identical and the DBD of ERp is 96% 
conserved compared to that of ERa, their sequences are only 58% similar in terms of 
the LDB (Mosselman et a l , 1996). Besides, ERP lacks A F-1. 
Estrogen receptors are widely distributed inside the body. ERa is expressed in 
tissue like the breast, bone, cardiovascular system, and so forth, while ERp is 
expressed in the breast, gastrointestinal tract, central nervous system, etc. In liver, 
both receptors are expressed, but expression level of ERais much higher than that of 
ERp(Gustafsson, 1999). 
1.2.2 LIGANDS FOR E R S 
The highly conserved structure in LBDs of ERa and ERp implies similar 
ligands acceptance for both receptors. The most common physiological source of 
ligand is estrogen. Other compounds with structure similar to that of estrogen, like 
ICI 164,382, tamoxifen, raloxifene or phytoestrogens, also bind to ER. 
As aforementioned, ER is ligand-dependent in gene transcription. Different 
ligands may result dissimilar actions. Those ligands which mimic estrogen's action 
are called agonist, while those lead to opposite action are called antagonists. These 
actions are dependent on tissue type and dosage. For instance, raloxifene has been 
reported to be an antiestrogen in breast cancer tissue and the brain, but it shows 
estrogen-1 ike beneficial effects in bone and cardiovascular system. 
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Figure 1.3 Domain structure representations of human ERa and ERp isoforms 
(Kong et al., 2003) 
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1.2.3 MECHANISMS OF LIGANDS-ER COMPLEX IN GENE REGULATION 
ER activates gene transcription in response to ligand binding and undergoes 
conformational changes, forming either homodimers or heterodimers of the two 
isoforms and interacting directly or indirectly with promoter specific elements 
(Pettersson and Gustafsson, 2001). 
There are two classical interactions (Klinge, 2001). The first kind is direct 
binding, which the Mgand-ER complex binds directly to estrogen response element 
(ERE) and interacts with different co-factors and RNA polymerase to activate or 
inhibit gene transcription. The second way is called 'tethering'. In this case ER 
dimer does not bind to DNA but interact with another DMA-bound transcription 
factor. It stabilizes the DNA binding or recruits co-activators to the complex. One 
example of this mechanism is the interaction between ERa and Spl. ERa has been 
shown to interact with 17p-estradiol and enhance the formation of Spl-promoter 
complex of promoter of LDL receptor gene (Li et al., 2001), hcl-2 (Dong et al., 
1999), transforming growth factor a (Vyhlidal et al., 2000), and so forth. ERa also 
interacts with USF-I and USF-2 in the cathepsin D promoter (Xing and Archer, 
1998) while both isoforms enhance the activity of and interact with the transcription 
factor AP-i (Paech et al., 1997; Webb etal., 1999; Jakacka et al., 2001). 
ER also regulates gene in a non-genomic way. In vascular endothelial cells, 
estrogen rapidly induces nitric oxide production by activating the P[3-kinase-Akt 
pathway (Haynes et al., 2000). In this process, ERa is shown to interact with the p85 
subunit of PI3-kinase in a ligand-dependent manner (Simoncini et al., 2000). 
Resveratrol and estradiol rapidly activate MARK signaling through ERa and ERp in 
endothelial cells (Klinge et al., 2005). Fiithermore, estrogen antagonists ICI 182,780 
can block the 17p-estradiol-stimulated c-fos expression via the MARK pathway, 
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indicating the involvement of ER in the activation of secondary signaling pathway 
(Hennessy et al., 2005). 
1.2.4 LIGAND-INDEPENDENT E R ACTIVATION 
Apart from being bound by ligands, ER activity can also be stimulated in a 
ligand-independent manner by modulation of several kinase pathways including the 
mitogen-activated protein (MAP) kinase and protein kinase A (PKA) pathways. 
Both PKA and MAP kinase pathways mediate phosphorylation and recruitment of 
the steroid receptor coactivator (SRC) family of coactivators (Tremblay et al., 1999; 
Rowan et al., 2000). Ligand-independent ER activators that function via MAP 
kinase include epidermal growth factor, TGF-a, IGF-1, etc (Weigel et al., 1997； 
Patrone et al” 1998; Coleman et al , 2001). Activation of the PKA signaling pathway 
by 8-bromo-cAMPand cholera toxin also enhances ER phosphorylation and activity 
(Katzenellenbogen, 1996; Weigel etal , 1997). 
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1.3 AIMS AND SCOPES OF INVESTIGATION 
Phytoestrogens have been suggested to be partly responsible for the relatively 
low incidence rate in high soy-or-red-vvine-consuming populations. However, the 
underlying mechanisms are not fully understood. Investigating the molecular 
regulation helps us to determine how these dietary components are beneficial to our 
body. 
Treatment ot dyslipoproteinemia has been proven a successful strategy in the 
prevention of cardiovascular diseases in clinical trials (ScharnagI and Marz, 2005). 
Cholesterol lowering is hypothesized to be one of the actions exerted by 
phytoestrogens. The major aims of this investigation were to determine how 
phytoestrogens genistein, daidzein, equol and resveratrol could regulate the genes 
LDLR and APOAI, which are both important for regulation of serum cholesterol. As 
the phytoestrogens can bind to estrogen receptors, the involvement ofERa and ERp 
m regulation and other cell signaling pathways were investigated in the present study. 
Response elements on the promoters of these two genes were then investigated. The 
whole picture of regulation was also compared to that of 丨"Zp-estradiol (E2), the 
major estrogen in our body. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 CHEMICALS AND MATERIALS 
2.1.1 CHEMICALS 
Genistein, daidzein, equol and resveratrol, 17p-estradioI (E2) and the carrier 
solvent DMSO, The mitogen-activated protein (MAP) kinase inhibitor PD 98059, 
The protein kinase A (PKA) inhibitor myristoylated 14-22 amide and the protein 
kinase C (PKC) inhibitor bisindolylmaleimide I were purchased from chemical 
companies. All other chemicals, if not stated, were gifts or acquired from Sigma 
Chemicals. All details are stated in appendix 2. 
2.1.2 PLASMIDS 
ERp expression plasm id, mammalian expression vector pcDNA3.1+ and 
ERE-luciferase reporter plasm id C3-luc were gifts. Reporter plain id pTA-luc and 
retiilla luciferase control plasmids were purchased from outside. All details are 
stated in appendix 2. 
2.2 MAMMALIAN CELL CULTURE 
2.2.1 MAINTENANCE OF CELLS 
The hepatocarcinoma cell line HepG2 were incubated in phenol red free RPMI 
1640 media with 2 mol/L L-glutamine, 100,000 U/L penicillin and 100 g/L 
streptomycin, and 10% fetal bovine serum (FBS). The incubator was maintained at 
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37。C and 5% CO2 air. When cells reached about 80% confluence, the cells were then 
sun-cultured arrounding to the procedure which described in appendix 2 in details. 
2.2.2 PREPARATION OF CELLS STOCK 
Semi-confluent cells were harvested and transferred into a 2-ml freezing tube. 
The tube was then frozen and stored into liquid nitrogen for permanent storage. The 
detatiled procedures refer to appendix 2. 
2.2.3 CELL RECOVERY FROM LIQUID NITROGEN STOCK 
The cell stock was taken out from the liquid nitrogen tank and thawed 
immediately in a 37°C water bath. Cells were pelleted and was subsequently 
suspended in ned medium and plated on a 75 cm^ culture flask with incubation as 
stated in 2.2.1. Other detailed procedures were described in appendix 2. 
2.3 MANIPULATION OF D N A 
2 . 3 . 1 ISOLATION OF H E P G 2 GENOMIC D N A 
HepG2 genomic DNA was isolated using DNeasy"^^ Tissue Kit according to the 
manufacturer manual which was described in appendix 2 in details. 
2.3.2 SEPARATION AND PURIFICATION OF D N A FROM AGAROSE GEL 
The agarose gels were prepared with 1.5% (w / v) agarose dissloved in IX TAE 
buffer containing 0.5 |ig/ml ethidium bromide. The volumes of DNA samples were 
adjusted to 10 to 50 ]LII with water or the running buffer with addition of 6X loading 
buffer to a final concentration of IX. After loading the samples into the wells of the 
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gel, electrophoresis was performed at constant voltage of 90 to 125 V (10 to 14 V/ 
cm) in a gel tank containing appropriate IX TAE buffer. When electrophoresis was 
finished, DNA was visualized on a gel documentation system. 
The bands of interest were cut out and purified with the CONCERT™ Rapid 
Gel Extraction System according to the manufacturer manual which was described 
in appendix 2 in details. 
2.3.3 RESTRICTION DIGESTION OF D N A 
Restriction digestion was used to prepare DNA inserts for subcloning or for the 
confirmation of transformants. Plasmid DNA was mixed with restriction enzymes 
and the respective buffers according to manufacturer's manual which was stated in 
appendix 2. 
2.3.4 LIGATION OF D N A FRAGMENTS 
The DNA insert and vector were mixed and ligated with T4 ligase in suitable 
buffer. Detailed procedures refered to appendix 2. 
2.3.5 TRANSFORMATION OF D H 5 A 
. . . . .. - 、 . 
Detailed procedures were described in appendix 2. 
2.3.6 SMALL SCALE PURIFICATION OF PLASMIDS FROM D H 5 A 
A single colony of transformed DH5a on a plate was inoculated into 10 
ml of LBa丨叩 medium at 37。C with shaking overnight. The overnight culture was 
transferred into a microtube and pelleted, the supernatant was discarded. Plasmids 
were purified by Wizard Plus SV Miniprep DNA Purification System according to 
manufacturer's protocol which was described in appendix 2. 
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2.4 CONSTRUCTION OF EXPRESSION AND REPORTER 
PLASMIDS 
2.4.1 CONSTRUCTION OF ESTROGEN RECEPTOR a ( E R a ) EXPRESSION 
VECTORS 
The cDNA fragment encoding the full length of ERa was amplified by PGR 
and directionally cloned into mammalian expression vector pcDNA3.1+. Successful 
clones were confirmed by DNA sequencing (Marcogen Inc., Korea). Deatiled 
procedures were described in appendix 2. 
2.4.2 CONSTRUCTION OF REPORTER VECTORS OF LDLR PROMOTER 
AND THE RESPECTIVE MUTANTS 
The 5'flanking region of LDLR promoter and the respective truncation mutants 
were amplified by PGR and directionally cloned into firefly luciferase reporter 
pTA-luc. Deatiled procedures were described in appendix 2. 
2.4.3 CONSTRUCTION OF REPORTER VECTORS o? APOAI PROMOTER 
AND THE RESPECTIVE MUTANTS 
The 5'flanking region of APOAI promoter and the respective truncation 
mutants were amplified by PGR and directionally cloned into firefly luciferase 
reporter pTA-luc. Deatiled procedures were described in appendix 2. 
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2.5 DETERMINATION OF P R O M O T E R TRANSCRTIPTION 
ACTIVITIES 
2.5.1 TRANSIENT TRANSFECTION OF CELLS WITH E R ALPHA 
EXPRESSION VECTOR AND PROMOTER REPORTER USING 
LIPOFECTAMINE PLUS REAGENT 
Two day before transfection, the cells were trypsinized and counted. The cells 
were plated into 24-welI plate with density 0.7X10^ cells/wells in RPMI with 5% 
charcoal/dextran treated FBS. Transfection was carried using Lipofectamine Plus 
reagent according to manufacturer's procedures which were described in appendix 2 
in details. 
2.5.2 DUAL LUCIFERASE ASSAY 
Dual Luciferase assays were preformed according to manufacturer's instruction which were 
described in appendix 2 in details. 
2.6 SEMI-QUANTITATIVE AND QUANTITATIVE R T - P C R 
ASSAY 
2.6.1 TRANSIENT TRANSFECTION OF CELLS WITH E R ALPHA 
EXPRESSION VECTOR USING LIPOFECTAMINE P L U S REAGENT 
Two day before transfection, the cells were trypsinized and counted. The cells 
were plated into 12-well plate (Iwaki Corp.) with density 1.4X10^ cells/wells in 
RPMI with 5% charcoal/dextran treated FBS. Transfection was carried using 
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Lipofectamine Plus reagent according to manufacturer's procedures which were 
described in appendix 2 in details. 
2.6.2 ISOLATION OF R N A USING T R I Z O L ® REAGENT (LIFE 
TECHNOLOGY,USA) 
Total RNA was isolated from cells grown in 12-vvell plates in triplicates by 
Trizol Reagent as directed by manufacturers. Detailed procedures were described in 
appendix 2. 
2.6.3 QUANTIFICATION OF R N A 
Biophotometer (Eppendort) was used for quantification of nucleic acid. A 1 OD 
unit at 260 nm corresponds to 50 |ag/ml double-stranded DNA, 40 ^ig/ml single 
stranded DNA and RNA, 20 )ig/ml single-stranded oligonucleatide. The amount and 
purity of RNA were determined by measuring its absorbance at 260nm and 280nm. 
OD260 * 40 mg ml"' = Amount of RNA (mg ml"'). RNA isolated by this method 
exhibited a 260/280 ratio of > 1.6. 
2 .6 .4 FIRST STRAND cDNA SYNTHESIS 
A reverse transcription-polymerase chain reaction (RT-PCR) assay was used to 
quantities LDLR, APOAI, SREBP-1, SREBP-2, Spl, E吼 GADPH and -ACTIN 
mRNA level. Sequences in appendix 2 were utilized to amplify the target cDNAs 
separately after the first strand reaction. Detailed procedures were described in 
appendix 2. 
2.6.5 SEMI-QUANTITATIVE P C R REACTIONS 
Detailed procedures were described in appendix 2. 
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2.6.6 QUANTITATIVE P C R REACTIONS 
Real time PCR was used to quantify the relative expression level of LDLR 
and APOAI mRNA in the phytoestrogen-treated samples. The primers and the 
FAM-labelled probes of LDLR, APOA【and internal control GADPH were all 
purchased from Applied Biosystems. The reaction mixture was prepared according 
to the manufacturer's manual. Detailed procedures were described in appendix 2. 
2.7 WESTERN BLOTTING 
7X10^ HepG2 cells in 60mm dish were seeded two days before transient 
transfection of ERa. Treated cells were harvested and protein concentration was 
determined by Bicinchonic Acid Assay. Anti-ERa primary, anti-actin primary and 
secondary antibodies conjugated with horseradish peroxidase were used for protein 
detection. The targeted protein was visualized by autoradiography. Detailed 
procedures were described in appendix 2. 
2.8 STATISTICAL METHODS 
A Prism 3.0 software package (GraphPad Software, Inc., CA, U.S.A) was 
utilized for statistical analysis. The results, whenever applicable, were analyzed by 
two-tailed Student's t-test to determine if significant (P<0.05) differences observed. 
The results were expressed as means 士 SEM. 
36 
C H A P T E R 3 R E G U L A T I O N B Y P H Y S I O -
L O G I C A L L E V E L O F 1 7 P - E S T R A D I O L O N 
A P O L I P O P R O T E I N A-I A N D L O W - D E N S I T Y -
L I P O P R O T E I N R E C E P T O R I N H E P G 2 C E L L S 
3.1 INTRODUCTION 
It is widely accepted that estrogen plays a critical role in the prevention of CVD. 
According to the most recent statistics from American Heart Association (2004), 
males have a higher rate of prevalence of coronary heart diseases (CHD) than 
females in the same age group (Figure 3.1). Postmenopausal women are also having 
2 times higher CVD incidence rate than premenopausal women at the same age 
(Kannelet al., 1976). 
One of the physiological functions of estrogen is modulating plasma lipid 
profile. l7p-estradiol (E2), as shown in Figure 3.2, is the major form of estrogen. 
Dp-regulation of APOAI and LDLR by E2 has been shown in many studies. 4-fold 
induction of APOAI promoter transcription has been shown in the presence of lOuM 
of E2 in HepG2 cells (Lamon-Fava et al., 1999). However, the detailed mechanism 
of its control has not been deeply investigated. LDLR has been widely studied, and 
the up-regLilation by E2 has been demonstrated through ERa (Bruning et al., 2003) 
and tyrosine kinase (Distefano et al., 2002) in HepG2 cells. Whether the 
unphysiological concentration used in these studies reflects the actual situations 
inside the body is still questionable. In this study, InM of E2 was used to illustrate 
how APOAI and LDLR were regulated at a physiological condition. 
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Figure 3.1 Prevalence of Coronary Heart Disease by age and sex (American 
Heart Association, 2005) 
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3.2 RESULTS 
3.2.1 Determination of transient transfection functionality of estrogen receptors 
in HepG2 cells 
Expression of ERa protein was only present in HepG2 cells transfected with 
pcDNA3.1 +ERafor 1 or 2 days. The protein was absence in cells transfected with 
pcDNA3.1+ (FigLire3.2A). At the physiological concentration of E2, about 4-fold of 
induction was observed in the presence of ERa, and the induction was abolished by 
estrogen antagonist ICI 182,780 (Figure 3.3), Similar observations were seen for 
ERp. 
ERp mRNA were only produced in HepG2 cells upon transient transfection of 
pCI-Neo-ERp after I or 2 days but not in those transfected with pCI-Neo only 
(Figure 3.2B). 
3.2.2 Effect of 17p-Estradiol on LDLR promoter transcription activity 
Physiological concentration of 17p-Estradiol could induce LDLR promoter 
transcription activity up to 3-fold in the presence of ERa (Figure3.4A). However, 
such induction was not observed when ERp was transfected (Figure3.4B). 
Furthermore, the treatment of MAP kinase inhibitor (PD 98059), PKA inhibitor 
(myristoylated 14-22 amide) or PKC inhibitor (isindolylmaleimide I) did not abolish 
the 17p-EstradioI induced LDLR promoter transcription activity in the presence of 
ERa (Figure 3.5). 
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3.2.3 Effect of 17p-Estradiol on APOAl promoter transcription activity 
Physiological concentration of 17(3-Estradiol could induce APOAl promoter 
transcription activity up to 6-fold in the presence of ERa (Figure3.6A). However, 
such induction was not observed when ERp was transfected (Figure3.6B). 
Furthermore, treatment of both MAP kinase inhibitor PD 98059, PKA inhibitor 
myristoylated 14-22 amide and PKC inhibitor isindolylmaleimide I did not abolish 
the I yp-Estradiol induced APOAl promoter transcription activity in the presence of 
ERa (Figure 3.7). 
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Figure 3.2 Expression of ERa protein and ER p mRNA in HepG2 cells after 
transient transfection of pcDNA3.1+ERa and pCI-Neo-ERp respectively. (A) 
Lanes 1 and 2 are samples extracted from HepG2 cells 48 hours and 24 hours after 
transient transfection of ERa; lane 3 is protein extracted from HepG2 cells 1 day 
after transient transfection of pcDNA3.1+. (B) Lane 1,2 and 5,6 were samples 
isolated from HepG2 cells 1 or 2 days after transient transfection of ERp; lane 3,4 
and 7,8 were samples extracted from HepG2 cells 1 or 2 days after transient 
transfection of pCI-Neo. 
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Figure 3.3 Effect ot pliysioiogical concentration of 17p-Estradiol on ERa 
transactivatioii activities in HepG2 cells. HepG2 cells were seeded in 24 wells 
plate and transfected with ERa expression, ERE-luciferase reporter and control 
plasmids for 24 hours. Different combinations of drugs (EtOH+DMSO, InM 
E2+DMS0 and InM E2+ICI 182,780) were added to treat the cells for 24 hours. 
The cells were finally lysed and dual luciferase activities were measured. Values are 
mean 土SEM.’ n=3. Means marked (*) or (#) significantly (P<0.05) differ between 
ERa+ve and ERa-ve under the same treatment. 
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Figure 3.4 Effect of 17p-Estradiol on LDLR promoter transcription activity in 
the presence of E R a or ERp. HepG2 cells were seeded in 24 wells plate and 
transfected with (A) ERa expression or pcDNA3.1+ vector and (B) ERp expression 
or pCI-Neo vector, together with IDL/^-luciferase and control reporter plasmids for 
24 hours. InM 17(3-Estradiol was administered and incubated for 24 hours. The cells 
were finally lysed and dual luciferase activities were measured. Values are mean 
士SEM, n=3. Means marked (*) significantly (P<0.05) differ from control (OnM). 
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Figure 3.5 Effect of M A P Kinase, PKA and PKC inhibition on 17p-Estradiol 
activation of LDLR promoter transcription. HepG2 cells were transient 
transfected with ERa expression vector, IDL/^-luciferase and control vector. After 
24 hours of transaction, cells were pretreated with MAP kinase inhibitor (PD 98059, 
10 uM), PKA inhibitor (myristoylated PKl 14-22 amide, 10 uM) and PKC 
inhibitor (bisindolylmaleimide I, 1 uM) pathways for I hour. InM E2 was then 
added, and cells were lysed after further 24 hours incubation with dual luciferase 
activities measurement. Values are mean 土SEM.’ n=3. Means marked (*) are 
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Figure 3.6 Effect of 17(3-Estradiol on APOAl promoter transcription activity in 
the presence of E R a or ERp. HepG2 cells were seeded in 24 wells plate and 
co-transfected with (A) ERa expression or pcDNA3.I+ vector and (B) ERp 
expression or pCI-Neo vector, together with .4TOy4/-liiciferase and control reporter 
plasmids for 24 hours. InM 17p-Estradiol was administered and incubated for 24 
hours. The cells were finally lysed and dual luciferase activities were measured. 
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Figure 3.7 Effect oi M A P Kinase, PKA and PKC inhibition on 17p-Estradiol 
activation of APOAI promoter transcription. HepG2 cells were transient 
transfected with ERa expression vector, ///YX4/-luciferase and control vectors. After 
24 hours of transfection, cells were pretreated with MAP kinase inhibitor (PD 98059, 
10 uM), PKA inhibitor (myristoylated PKI 14—22 amide, 10 uM) and PKC inhibitor 
(bisindolylmaleimide I, 1 uM) pathways for I hour. InM E2 was then added, and 
cells were lysed after further 24 hours incubation with dual luciferase activities 
measurement. Values are mean 土SEM.’ n=3. Means marked (*) are significantly 
(P<0.05) difTer from group subjected the same inhibitor treatment. 
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3.3 DISSUSIONS 
The functional expression of estrogen receptors was critical as it dictated the 
validity of the whole study. Western blotting and RT-PCR demonstrated the 
expression of ERa protein and ER(3 mRMA upon transient transfection. 
Functionality of the receptors had been confirmed by the induction of human 
complement C3 promoter transcription activities. The promoter contained 2 half 
sites of ERE and the respective luciferase activity was induced by 5.6-fold upon 
lOnM E2 treatment (Fan et al., 1996). This result validated the model system 
employed. 
The induction of LDLR and APOAI promoter transcription by E2 at the 
physiological level provided an explanation for premenopausal women having a 
lower incidence rate of CVD than men and postmenopausal women. Such increases 
only occurred in the presence of ERa but not in other cases. The failure of inducing 
LDLR and APOAI transcription by ERp might be due to the structural differences in 
N-terminal between the two isoforms. Sequence homology of the N-terminal region 
between ERa and ERp is only about 15% and its importance in gene regulation has 
been raised in many past studies (Warnmark et al., 2001). AF-1 at the N-terminal, 
which ERp lacks, has been shown to be critical in the activation of LDLR • 
transcription (Li et al., 2001). 
Neither LDLR nor APOAI promoter contains any functional consensus ERE 
sites, therefore the induction by E2 in the presence of ERa was probably not through 
direct binding but interacting with other transcription factors bound to the cognate 
sites in the promoters (Sukovich et al., 1994). Treatment of high dosage of E2 at 
lOOnM activates Spl binding in the transcription of LDLR (Li et al., 2001). 
17p-estradiol might not regulate the genes by non-genomic events as cell 
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signaling pathways were not implicated in the activation of transcription for both 
genes. The failure of suppression of induction by inhibitors of MAP kinases, PKA 
and PKC supported this notion. 
In conclusion, ERa was important in the gene regulation of LDLR and APOAI 
under physiological level of E2. Such transcription regulation appeared to be 
independent of MAP kinase, PKA and PKC. 
48 
C H A P T E R 4 S O Y I S O F L A V O N E S A N D 
R E S V E R A T R O L D I S P L A Y D I F F E R E N T 
M E C H A N I S M S I N T H E U P R E G U L A T I O N O F 
L O W - D E N S I T Y L I P O P R O T E I N R E C E P T O R I N 
H E P G 2 C E L L S 
4.1 INTRODUCTION 
The human gene LDLR is mapped at chromosome 19, which is more than 45 
kilobases in length. It contains 18 exons separated by 17 introns. The matured 
receptor contains 5 domains. The first domain is the binding domain. The second 
domain has been found to be homologous to a portion of extracellular domain of 
EGF precursor. The third domain serves as an attachment site on the cellular 
membrane while the forth domain is a membrane-spanning region. The last domain 
is a cytoplasmic tail (Sudhof et al., 1985). 
LDLR is a surface glycoprotein which plays a very important role in regulating 
plasma cholesterol. The hepatic LDLR is the major form of high affinity receptor for 
apolipoproteins B-lOO and E, which are the main components of LDL. The LDLR is 
mainly localized in the coated pits of liver cells. Upon the binding of LDL, the 
receptor complex undergoes endocytosis and enters into the cytoplasm to attach to 
lysosomes. LDL particles are then broken down by lysosomes. The protein 
components of LDL particle are hydrolyzed to free amino acids while the 
cholesterol esters are degraded by lysosomal acid lipase. The degraded products 
form bile acids which are transported to large intestine for excretion. The LDLR 
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returns back to plasma membrane. Therefore, the presence of LDLR prevents excess 
cholesterol circulating in the bloodstream (Catapano, 1989). Figure 4.1 A illustrates 
the LDLR and LDL cycles in liver cells. 
Previous studies have suggested that increased amount of LDLR in liver 
reduces blood cholesterol level. The reduction of plasma cholesterol by dietary 
isoflavones has been only observed in normal mice but not in those with LDLR 
deficiency (Kirk et al., 1998). Red wine polyphenolics also increased LDLR 
expression and activity in human HepG2 cells (Pal et al., 2003). 
The 5'-flanking region of human LDLR gene plays an important role in the 
regulation of the expression of the gene. This region has been isolated and studied 
for 20 years (Sudhof et al., 1985). Three imperfect direct repeats and a TATA-like 
sequence have been identified to be the core requirement for LDLR gene expression 
(Sudhof et al., 1987a; Sudhof et al., 1987b). The three repeats have been designated 
as repeat 1 (from -81 to -96), repeat 2 (from -45 to -61) and repeat 3 (from -128 to 
-144). Figure 4.1 B shows the respective nucleotide sequence annotated with 
recognized response elements. 
Repeat 2 is subjected to the regulation by intracellular cholesterol. Cholesterol 
activates sterol-sensitive proteases which cleave the membrane anchored 
sterol-regulatory element binding protein (SREBP)-l and -2 (Brown and Goldstein, 
1997). Therefore repeat 2 is also termed as sterol regulatory cw-element (SRE). 
Other growth factors, like insulin, insulin like factor and platelet derived growth 
factor, also stimulate LDLR expression via this element (Streicher et al., 1996). 
Repeat 1 and repeat 3 contain Spl-binding sites that support the basal 
transcriptional activity of LDLR. Interactions of Spl to the proximal binding site in 
repeat 3 and to the distal binding site in repeat 1 are required for the normal maximal 
transcriptional activity of the LDLR. Interruption of Spl binding to either repeats 
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severely decreases basal transcription. For example, a 3-bp deletion in the R1 region 
of the LDLR promoter has been identified in a patient with a clinical diagnosis of 
familial hypercholesterolemia (Peeters et al., 1998). Spl binding to the mutated R1 
sequence is abolished, and LDLR gene expression in fibroblasts from the patient is 
severely decreased. Recent studies have shown that the interaction of SREBP with 
SRE-1 increases the binding of Spl to R3, thereby resulting in a synergistic 
activation (Sanchez et al., 1995; Bennett and Osborne, 2000). 
Apart from the three repeats, promoter region -110 to -92 has been identified as 
sterol-independent regulatory element (SIRE), which is critical for oncostatin M 
regulation of LDLR. This region overlaps with the TATA-1 ike sequence and contains 
an active C/EBP site (-110 to -102) and a functional cAMP responsive element 
(CRE) (-101 to -92) (Liu et al, 2000). Footprint 1 (FPl) (-297 to-279) is another 
identified region for LDLR gene transcription. Transcriptional induction of LDLR 
has been found to be mediated by this region under sterol depleted conditions 
(Mehta et al., 1996). 
In previous experiments, phytoestrogens have been found to induce LDLR 
promoter transcription. In the present study, response elements involved in the 
lip-regulations were investigated 
In this part of study, the molecular mechanism of regulation of LDLR by 
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ggatcccaca aaacaaaaaa tatttttttg gctgtacttt tgtgaagatt ttatttaaat 
-687 
tcctgattga tcagtgtcta ttaggtgatt tggaataaca atgtaaaaac aatatacaac 
-627 
gaaaggaagc taaaaatcta tacacaattc ctagaaagga aaaggcaaat atagaaagtg 
-567 
gcggaagttc ccaacatttt tagtgttttc cttttgaggc agagaggaca atggcattag 
-507 
gctattggag gatcttgaaa ggctgttgtt atccttctgt ggacaacaac agcaaaatgt 
-447 
taacagttaa acatcgagaa atttcaggag gatctttcag aagatgcgtt tccaattttg 
-387 
agggggcgtc agctcttcac cggagaccca aatacaacaa atcaagtcgc ctgccctggc 
-327 FPl 
gacactttcg aaggactgga gtgggaatca gagcttcacg ggttaaaagc cgatgtcaca 
-267 Repeat 1 Repeat 2 
tcggccgttc gaaactcctc ctcttgcagt gaggtgaaga catttgaaaa tcaccccact 
-207 Repeat 3 TATA TATA CRE 1 i i 
gcaaactcct ccccctgcta gaaacctcac dittgaaatgc igtaa^jgfi^c gtgggcccflg 
-147 
\ i i * 
a|t|caat|g cgggaagcca gggtttccag c|aggacaca gcaggtcgtg atccgggt|g 
-87 * 
ggacactgcc tggcagaggc tgcgagcar^ gggccctggg gctggaaatt gcgctggacc 
-27 +1 
gtcgccttgc tcctcgccgc ggcggggact gcaggtaagg cttgctcca 
Figure 4.2 Nucleotide sequences of the 5，end of the human LDL receptor gene 
(Adapted from Sudhofet al., 1985) 
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4.2 RESULTS 
4.2.1 Association of ERa and isoflavones or resveratrol on LDLR promoter 
transcription activity 
In the presence of ERa, all three isoflavones could increase LDLR promoter 
transcription activities in a dose-dependent manner. The trend was similar to that of 
l7p-estradiol. Genistein induced the activity by 2 fold at 0.1 uM while over 5-fold 
increase was observed at lOuM (Figure 4.3A); daidzein showed a 2-fold induction at 
0.1 uM to around 6-fold at lOuM (Figure 4.3B); equol displayed the greatest increase, 
from 3 fold at 0.1 uM to about 12.5 fold at lOuM (Figure 4.3C). Slight inductions 
were also observed in high dosage of daidzein and equol in the absence of ERa 
(Figure 4.3 Band 4.3C). 
Unlike isoflavones, resveratrol regulated LDLR promoter transcription in an 
ERa-independent manner. No matter ERa was presence or not, it showed a much 
lower induction than that of isoflavones, i.e. around 2 fold at lOuM (Figure 4.4). 
4.2.2 Association of ERp and isoflavones or resveratrol on LDLR promoter 
transcription activity 
All the phytoestrogens exhibited non-ERp dependent manner in LDLR 
promoter transcription activities. Genistein at lOuM showed approximately a 
<2-fold increase (Figure 4.5A), while both daidzein and equol showed about 
2.5-fold induction at lOuM (Figure 4.5B and 4.5C). Resveratrol had a minimal 
induction of 1.5 fold (Figure 4.6). 
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4.2.3 Role of M A P Kinase，PKA and PKC in isoflavones and resveratrol 
induced L D L R promoter transcription. 
Upon the pretreatnient of inhibitors of MAP kinase, PKA and PKC pathways, 
None of the isoflavones tested showed reduced LDLR promoter transcription in the 
presence of ERa (Figure 4.7). Further increase in transcription activity resulted 
when iSofiavone-treated cells were pre-treated with MAP kinase inhibitor (Figure 
4.7). 
Similar to the results of isoflavones, no transcription inhibition was observed 
upon pre-treatments with MAPK, PKA and PKC inhibitors in resveratrol-treated 
cells (Figure 4.8). However, different pattern of inhibition was demonstrated when 
there was no ERa. Although no inhibition occurred upon pre-treatments of inhibitors 
of MAP kinase and PKA, upon the pre-treatment of PKC inhibitors, 
resveratrol-indiiced transcriptional activitiy was not as high as that 
without-pretreatment (Figure 4.8). 
4.2.4 Identification of promoter regions responsible for induction of L D L R 
transcription by isoflavones in the presence of ERa 
The major region which was responsible for induction of LDLR transcription 
by isoflavones was located at region -202 to -127. There was a sharp decrease in 
luciferase activity when this region was deleted in cells treated with 0.5|iM and 
lOi^M genistein. Slight decrease was also observed when the region -447 to -202 
was deleted (Figure 4.9). 
The region -202 to -127 contains the three repeats and two TATA box. To 
further identify the specific responsive region, different point mutants of repeats 
were used for analysis. The greatest reductions of luciferase acivities were observed 
in R3mut and RlR3mut where repeat 3 and both repeat 1 and 3 were mutated 
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respectively. Rlmut and Rlmut also showed decreases but the drop was less than 
that of R3mLit (Figure 4.10). 
Expression on transcription factors SREBP-1, SREBP-2 and Spl were also 
examined upon isoflavones treatment. Slight induction of SREBP-2 was observed at 
genistein treatment at luM, while expression of SREBP-1 was induced in all 
isoflavones treatment. Spl expression was not affected (Figure 4.11). 
4.2.5 Identification of promoter regions responsible for induction of Idlr 
transcription by resveratrol in the absence of ERa 
The major region responsible for the induction of LDLR transcription by 
resveratrol was located at region -447 to -202 and -202 to -127. There were sharp 
decreases in luciferase activity when this region was deleted in cells treated with 
0.5uM and lOuM resveratrol (Figure 4.12). 
Similar to soy isoflavones, the greatest reduction of luciferase activities were 
observed in R3mut and RlRSmut. Rlmut and R2mut also showed decreases slightly 
(Figure 4.13). 
Expression on transcription factors SREBP-I, SREBP-2 and Spl were also 
examined. About 3-fold induction of SREBP-2 was observed at resveratrol treatment 





t~~]ERa -ve , 
[ZZlERa +ve * # 
5-
m I — 
c * 
.2 4-
I # n 
.E . # I ~ 
0 q # * 
1 n r ^ 
U^  2- p - * 
1- r i i fh _ _ _ 






1 I ERa +ve 丁 
c m ERa -ve 
c 
0 
•-g 5.0- # 
1 # q 
— # 1— * * 
5 门 * r ^ # 
£ 2.5- 门 * 
广《 ~ 
rM _ , 、； • 
J I kl m m ki M 卜二 






c:::::J ERa +ve * 
12.5 c::::J ERa -ve 
c: 
0 
;: 10.0 (.) # # ::l 
"0 # ~ c: 7.5 # J * '0 ~ * "0 "0 5.0 't- * * 2.5 
0.0 
0.0 0.1 0.5 1.0 10.0 E2 
Equol (uM) 
Figure 4.3 Effect of isoflavones on LDLR promoter transcription activity in the 
presence of ERa. HepG2 cells were seeded, in 24 wells plate, and co-transfected 
with ERa expression vector or pcDNA3.1 +, LDLR-Iuciferase and control reporter 
was carried out for 24 hours. (A) Genistein, (8) daidzein and (C) equol at ~uM, 
0.1 uM, 0.5uM, I uM and t OuM were administered. Treatment with 170-Estradiol 
was a positive control. The cells were finally lysed and dual luciferase activities 
were measured. Values are mean ±SEM, n=3. Means marked (*) and (#) are 
significantly (P<0.05) differ from control (OnM) and same drug treatement 
respecti ve I y. 
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Figure 4.4 Effect of resveratrol on LDLR promoter transcription activity in the 
presence of ERa. HepG2 cells were seeded in 24 wells plate and co-transfected 
with ERa expression vector or pcDNA3.l+, IDI/?-luciferase and control reporter 
was carried out for 24 hours. Resveratrol at OuM, 0.1 uM, 0.5uM, luM and lOuM 
were administered. Treatment with l7P-Estradiol was a positive control. The cells 
were finally lysed and dual luciferase activities were measured. Values are mean 
土SEM, n=3. Means marked (*) and (#) are significantly (P<0.05) differ from control 




3"! CZDERp +\/e ^ 
m m ER6 -ve H 
* 
c 丁 K ^ l .2 2 - — 
0 mi 
1 . I _ „ 
方 M J n • 、 F _ H 
2 ^ H ® r ^ 翻 國 _ 
_ • F F i _ im • m _ m _ m _ 
0 0.1 0.5 1 10 E2 
Equol (uM) 
Figure 4.5 Effect of isoflavones and resveratrol on LDLR promoter 
transcription activity in the presence of ERp. HepG2 cells were seeded in 24 
wells plate and co-transfected with ERp expression vector or pCl-Neo, 
IZ)!/^-luciferase and control reporter was carried out for 24 hours. (A) Genistein, (B) 
daidzein and (C) equol at OuM, 0.1 uM, 0.5uM, luM and lOuM were administered. 
Treatment with 17p-Estradiol was a positive control. The cells were finally lysed 
and dual luciferase activities were measured. Values are mean 士SEM, n=3. Means 
marked (*) and (#) are significantly (P<0.05) differ from control (OnM) and same 
drug treatment respectively. 
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Figure 4.6 Effect of resveratrol on LDLR promoter transcription activity in the 
presence of ERp . HepG2 cells were seeded in 24 wells plate and co-transfected 
with ERp expression vector or pCI-Neo, LDZJMuciferase and control reporter was 
carried out for 24 hours. Resveratrol at OuM, 0.1 uM, 0.5uM, luM and lOuM were 
administered. Treatment with 17(3-Estradiol was a positive control. The cells were 
finally lysed and dual luciferase activities were measured. Values are mean 土SEM, 
n=3. Means marked (*) and (#) are significantly (P<0.05) differ from control (OnM) 
and same drug treatment respectively. 
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Figure 4.7 Effect of M A P Kinase，PKA and PKC inhibition on isoflavones 
activation of LDLR promoter transcription in the presence of ERa . HepG2 cells 
were transfected with ERa expression vector, luciferase and control vectors. 
After 24 hours transfection, cells were pretreated with inhibitors of MAP kinase, 
PKA or PKC pathways for I hour. luM of each isoflavones were then added, cells 
were lysed after further 24 hours followed by dual luciferase activities measurement. 
Values are mean 士SEM., n=3. Means marked (*) are significantly (P<0.05) differ 
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Figure 4.8 Effect of MAP Kinase PKA and PKC inhibition on resveratrol 
activation of LDLR promoter transcription in the absence of ERa. HepG2 cells 
were transient transfected with pcDNA3.1+, luciferase and control vectors. 
After 24 hours transfection, cells were pretreated with inhibitors of MAP kinase, 
PKA or PKC pathways for 1 hour. lOuM resveratrol was then added, cells were 
lysed followed by dual luciferase activities measurement. Values are mean 土SEM.， 
n=3. Means marked (*) are significantly (P<0.05) differ from group subjected the 
same inhibitor treatment. 
64 
4.9A 
E2 ^ ^ ^ ^ i ^ M i a M ^ a B M K H _ | 
£ wtmmmtmmmmmmr^ — H 
W  
c .、广 V 务* ^ I —I 
(r) i ^ ^ s ^ ^ ^ ^ ^ ^ ^g i aBB i i i i Ba ^ i SB^^ * 
S S S S S T ^ ^ ^ ^ I * 
IZ23 -687Idlr 
:.-.,:、-,:”妻-、:.•動 -447ldlr 
0 • -202ldlr 
P i y ™ * " " ! * M-127ldlr 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 
Normalized luciferase values (arbitary unit) 
4.9B 
~ ~ — — — * E2 
mmmm ^ * 
:~.、〜、‘、嫩 w 麟 ” ” 、 ’ . 广 丄 , “ • H 
之 10 I I I III IIII I 丨 I 丨丨 Ill * 




H H B - — — I * 
EZSI -687ldlr 
i f f l -447ldlr 
0 HSH-202ldlr 
"I * •-127 jd l r 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 
Normalized luciferase values (arbitary unit) 
65 
4.9C 
. : . 梵 > [H 1 
E 2 * 
1 Q M.T.-^ -^^ M^ w.r.n n— -, •, i !• •!!• •• I^IIB m 
o 
3 
jS" . , � . -、 - ^ t <•中. H 
C H H - — ^ * 
-687ldlr 
|| M l -447ldlr 
^^^^ 國-202lclr 
P S T ^ *  
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 
Normalized luciferase values (arbitary unit) 
-687M -687 I I +77 
-4471(11 -447 +77 
-2021(11 -202 纖 嫩 職 + 7 7 
-nihil -127 • • • • H H H +77 
Figure 4.9 Identification of LDLR promoter regions iiivolved In the expression 
up-regulated by isoflavones in the presence of ERa. HepG2 cells were seeded in 
24 well plate and co-transfected with ERa expression vector and equal molar of 
truncated reporter plamids. (A) Genistein, (B) daidzein or (C) equol at OuM, 0.5uM, 
and lOuM were administered for 24 hours. Treatment with IVP-Estradiol was the 
positive control. The cells were finally lysed and dual luciferase activities were 
measured. Values are mean ±SEM, n=3. Means marked (*) are significantly (P<0.05) 
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Figure 4.10 Characterization of the isoflavones response region in Idlr promoter 
in the presence of ERa. HepG2 cells were seeded in 24 well plate and 
co-transfected with ERa expression vector and equal molar of point mutated reporter 
plamids. (A) Genistein, (8) daidzein or (C) equol at ~uM, O.SuM, and lOuM were 
administered for 24 hours. Treatment with 17p-Estradiol was the positive control. 
The cells were finally lysed and dual luciferase activities were measured. Values are 
mean ±SEM, n=3. Means marked (*) are significantly (P<O.OS) lower than the value 
of wildtype (-202/+77) promoter in the same drug treatment. 
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Figure 4.11 Expression of transcription factors upon isoflavones treatment in 
the presence of ERa. HepG2 cells were seeded in 12 well plates. Transfection of 
ERa expression vector was carried out for 24 hours. After that, the cells were treated 
with (A) genistein, (B) daidzein or (C) equol at OuM, kiM and lOuM in tripliates. 
l7p-Estradiol was the positive control. RNA of cells was 
then extracted. RT-RCP 
was carried out to quantify the relative expression level of SREBP-1, SREBP-2 and 
Spl. Optical density was then measured. Means marked (*) are significantly {P<0.05) 
higher than control. 71 
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Figure 4.12 Identitication of Idlr prombter regions involved in the expression 
up-regulated by resveratrol in the absence of ERa. HepG2 cells were seeded in 
24 well plate and co-transfected with pcDNA3.1+ vector and equal molar of 
truncated reporter plasmids. Resveratrol at OuM, 0.5uM, and I OuM were 
administered for 24 hours. The cells were finally lysed and dual luciferase activities 
were measured. Values are mean 土SEM, n=3. Means marked (*) are significantly 




I,v, i!hil R1 mut 
~R2mut 
_R3mut 
IIIIlJ R 1 R3mut 
0.0 0.5 1.0 1.5 2.0 
Normalized luciferase value (arbitary unit) 




-202 ~~~~~~~"""~""~~~~'*'''~~ +77 
R1 R2 ~ TATA R3Mut -202 +77 
RI R3Mut -202 IIIIIIIIIIIIIIII~IIIIIIII Rll" III~" III ttNl1A1I1I1I111I1 +77 
2.5 
Figure 4.13 Characterization of the resveratrol response region in Idlr promoter· 
in the absence of ERa. HepG2 cells were seeded in 24 well plate and co-transfected 
with pcDNA3.1 + vector and equal molar of point mutated reporter plasmids. 
Resveratrol at OuM, 0.5uM, and 10uM were administered for 24 hours. The cells 
were finally lysed and dual luciferase activities were measured. Values are mean 
±SEM, n=3. Means marked (*) are significantly (P<O.05) lower than the value of 
wildtype (-202/+77) promoter in the same drug treatment. 
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Figure 4.14 Expression of transcription factors upon genistein treatment in the 
presence of ERa. HepG2 cells were seeded in 12 well plates. Transfection of ERa 
expression vector was carried out for 24 hours. After that, the cells were treated with 
resveratrol at OuM, luM and lOuM in triplicates. RNA of cells was then extracted. 
RT-RCP was carried out to quantify the relative expression level of SREBP-1, 
SREBP-2 and Spl. Optical density was then measured. Means marked (*) are 
significantly (P<0.05) higher than control. 
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4.3 DISCUSSION 
Isoflavones have previously been shown to reduce plasma cholesterol and 
atherosclerosis in normal mice but not in those with LDLR deficiency (Kirk et al., 
1998). A clinical study has also demonstrated the hypocholesterolemic effect of soy 
protein with isoflavones, accompaning with the increase in LDLR mRNA in 
mononuclear cell in hypercholesterolemic, postmenopausal women (Baum et al., 
1998). However, the detailed mechanisms have not been fully illustrated. 
Psychological concentration of 17p-Estradiol has been demonstrated to regulate 
LDLR transcription through ERa in Chapter 2. Therefore, it is hypothesized that ERa 
may also be involved in phytoestrogens' regulations. 
In the present study, the specific effect of each isoflavones and resveratrol to 
hepatic LDLR expression was demonstrated. All the tested phytoestrogens induced 
LDLR promoter transcription activities in a dose-dependent manner, demonstrating 
that the CVD protective effect of soy isoflavones and resveratrol might due to the 
increased hepatic LDLR transcription which controls the protein expression level. 
The results also indicated the importance of ERa was different in the regulation by 
isoflavones and resveratrol. Only isoflavones regulated LDLR transcription through 
RRa. Generally, after ligands bind to ER, it dimerizes before activating gene 
expression or initiate other cell-signaling pathway. In the presence study, whether 
ERa dimerized to activate LDLR promoter activity was not known. 
Isoflavone administration resulted a greater increase than resveratrol. This 
might be due to the weak binding affinity of resveratrol when compared to those of 
isoflavones (Mueller et al., 2004). Although resveratrol induced LDLR 
transactivation, this occurred only at iinphysiological concentration as high as 10|J,M. 
Very few researches have focused the possibility of resveratrol to regulate LDLR. 
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Most studies suggested that the protective effect of red wine polyphenols against 
CVD is due to anti-oxidation of LDL in plasma (Frankel et al., 1993; Fremont et al., 
1999; Brito et al., 2002; Ferroni et al., 2004; Ou et al., 2005). Only a cell culture 
study has demonstrated that red wine polyphenols increased expression of LDL 
receptor (Pal et al., 2003). When considering the physiological concentrations, only 
isoflavones showed the potential to induce LDLR expression. In soy-consuming 
population, genistein is the major form of phytoestrogen in plasma. (Morton et al., 
2002) Therefore, the major contributor of LDLR induction could be genistein. 
Among all isoflavones, genistein is the most potent ER agonist (Latonnelle et 
al., 2002). However, it was interesting that daidzein and equol displayed a 
significantly higher induction at lOjjJVl than that of genistein. ERE was not present in 
the promoter of LDLR. Hence, the differences in affinity towards the classic estrogen 
response element (GGTCAnnnTGACC) (Klinge, 2001), could not account for the 
observation. The confirmational changes upon equol and daidzein binding might 
favour binding to response elements present in LDLR promoter other than ERE. 
ERa, but not ERp was involved in the regulation of LDLR transcription. Even 
though all phytoestrogens tested were ligands for ERp, the affinities of isoflavones 
towards ERp are less than that of ERa, which is supported by previous studies 
concerning ER-mediated core hi stone acetylation (Hong et al., 2004) and 
transcription activity to ERE (Mueller et al., 2004). Besides this, the lacking of AF-1 
might account for the observation as previously mentioned in Chapter 3. 
As mentioned in Introduction, ERa regulates gene expression in a 
genomic-dependent and.-independent pathway. Either way may be involved other 
cell signaling pathways. Hence, cells were pre-treated with inhibitors of different 
secondary signaling messagers for examination. Inhibitors of MAP kinase, PKA and 
PKC did not abolish the LDLR transcription induced by isoflavones in cells 
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expressing ERa. These results indicated two things. Firstly, apart from ligand 
binding, phosphorylation of ERa can be directly activated via MAK kinase (Arnold 
et al., 1995; Bunone et al., 1996) and PKA (Chen et al., 1999). The results here 
showed that ERa phosphorylation did not affect either one. Secondly, although MAK 
kinase and protein kinase C have previously been found to be involved in LDLR 
transcription in HepG2 cells (Kapoor et al., 2003) and ligand-ERa has been 
demonstrated to activate downstream MAP kinase and PKA signaling pathways 
(Yamakawa and Arita, 2004; Pawlak et al., 2005), these enzymes were not involved 
in the downstream metabolism of ERa-dependent transcription in this study. The 
above suggests a possibility of the genomic involvement of ERa in LDLR regulation 
by isoflavones. 
As aforementioned, resveratrol induced LDLR transcription only at a high 
concentration in ERa or ERp independent pathway in this study. Resveratrol is a 
protein kinase C inhibitor with IC50 of 2liM (Slater et al., 2003) and also an activator 
of MAP kinase (Miloso et al., 1999; Klinge et al., 2005). In the regulation by 
resveratrol, none of these inhibitors suppressed the induced LDLR transcription. 
Therefore, MAP kinase, PKA and especially PKC were not involved in the 
resveratrol-induced transcription. Tyrosine kinase (TK) has been demonstrated to be 
involved in estradiol-induced LDLR transcription (Distefano et al., 2002). As 
resveratrol has been shown to be the inhibitor of it (Palmieri et al., 1999), the 
participation of TK in the regulation is unlikely. Resveratrol may regulate LDLR 
transcription by affecting the expression of transcription factors. 
Previously 17p-estradioI and tamoxifen has been shown to regulate LDLR 
though binding to ERa and interacting with Spl, and R3 is the response element 
(Bruning et al., 2003). In the present study, all repeats showed involvement in the 
control of transcription of LDLR under the treatment of phytoestrogens. Among the 
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three repeats, R3 was the most critical one. 
Among all repeats, R3mut and RlR3mut have the greatest decreases in 
transcriptional activity, indicating that R3 was the most important response element 
among the three. Repeat 3 was the binding region which ERa might interact through 
Spl (Li et al., 2001; Bruning et al., 2003); thus the up-regulation by phytoestrogens 
might be dependent on Spl. Although Repeat 1 was also a Spl binding site, its 
imitant did not show a sharp decrease as R3 mutant. The sequences of Rl and R3 are 
very similar, but previous studies have not demonstrated Rl as an important 
regulatory response element. 
The phytoestrogens did not up-regulate the expression of transcription factor 
Spl. Apparently, isoflavone-ER complex facilitated the binding of Spl to the 
promoter region and increased LDLR transcriptional activities. 
Repeat 2 is a SREBP binding site. Mutated Repeat 2 also affected 
phytoestrogens' up-regulation of LDLR transcription. However, R2 might not 
directly couple with ERa and bind to the promoter. Instead, phytoestrogens might 
affect the nuclear concentrations of SREBPs. As shown in the RT-PCR result, gene 
expressions of SREBP-1 and -2 were slightly increased upon phytoestrogen 
treatment. SREBP-1 was mainly increased by isoflavones while resveratrol increased 
gene expression of SREBP-2. Promoter of SREBP-1 a has been shown to contain two 
Spl sites (Zhang et al., 2005). The isoflavone-ERa complex could have bound to the 
promoter and up-regulated the transcription in the present investigation. 
Phytoestrogen might also increase the proteolysis of the membrane bound SREBPs 
in a mode similar to the regulation by cholesterol (Brown and Goldstein, 1997). Soy 
extracts, genistein and daidzein have been shown previously to increase nuclear 
mature SREBP-2 in HepG2 cells (Mullen et al., 2004). It is not known whether 
resveratrol have this proteolytic effect. 
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Interestingly, both SREBP and Spl can induce LDLR transcription alone, but 
they can also cooperate in the induction. SREBP has been demonstrated to increase 
the binding of Spl to the adjacent R3 (Sanchez et al” 1995). The phytoestrogens in 
current study induced SREBP expression and it might also increase Spl binding to 
R3. 
In conclusion, all phytoestrogens up-regulated LDLR transcription. The 
regulation by isoflavones were dependent on ERa but that by resveratrol was not. 
Pre-treatment of inhibitors of MAP Kinase, PKA and PKC failed to abolish the 
induced transcription by all phytoestrogens, showing that the involvement of these 
secondary messagers was not possible. Region -201 to -127 was found to be 
important for all phytoestrogens' up-regulation. For resveratrol, apart from the 
aforementioned region, -447 to -202 might also be crucial. 
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C H A P T E R 5 S O Y I S O F L A V O N E S A N D 
R E S V E R A T R O L U P - R E G U L A T E A P O L I P O -
P R O T E I N A- I S I M I L A R T O 1 7 P - E S T R A D I O L I N 
H E P G 2 C E L L S 
5.1 INTRODUCTION 
The human gene APOAI is a member of the gene cluster APOAI-CIII-AIV 
which locates on chromosome 11 (Groenendijk et al., 2001). It 1.87 kilobases long 
and contains 4 exons and 3 introns. A matured APOAI protein is made up of 243 
amino acids. A large portion of its structure is a series of tandem ly repeated 22 amino 
acid segments in a predicted helical and amphiphilic structure (Mahley et al., 1984). 
APOAI plays two important roles in lipid metabolism. It is a major component 
in high density lipoprotein (HDL) (Mayes, 1993). HDL helps to deliver cholesterol 
back to the liver, which process is described as reverse cholesterol transport. It is 
also an obligatory co-factor for the cholesterol-esterifying enzyme 
lecithinicholesterol acyltransferase (LCAT). This enzyme facilitates cholesterol 
efflux for the formation of matured HDL-cholesterol. Therefore, APOAI is mediating 
the clearance of excess plasma cholesterol. Figure 6.1 illustrates the production of 
HDL. 
Expression of the APOAI gene is primarily regulated at the transcriptional level. 
The 5'-flanking region of the human APOAI gene has been isolated and 
characterized. APOAI expression is tissue specific. In liver, the major transcription 
start site is 235 base pairs upstream from the AUG translational start codon. TATA 
box-like sequence is 30 bp up-streams from the transcriptional start site. Several cis 
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elements affect the expression of the gene in a positive or negative manner in 
response to changes in the hormonal or metabolic status (Higuchi et al., 1988). An 
insulin response core element (IRCE) located at -411 to -404 is subjected to insulin 
(Lam et al., 2003) and epidermal growth factor (Zheng et al., 2001) induction. Spl 
also plays an important role in the transcription factor binding to this region. In the 
region -214 to -119, there are 3 fragments named site A (-214 to -192), site B (-169 
to -146) and site C (-134 to -119). Many transcription factors and nuclear receptors 
have been identified binding to these sites (Widom et al., 1991), for example, 
hepatocyte nuclear factors (HNF)-3 and -4 have been shown to bind to element A 
and element B respectively (Harnish et al., 1996). Figure 7.1 shows the nucleotide 
sequence of the 5'flanking region of APOAI gene annotated with identified response 
elements. 
In last chapter, the molecular mechanism of phytoestrogens on APOAI 
regulation was investigated and compared to that of 17p-estradiol, the response 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2.1 Association of ERa and phytoestrogens on APOAI gene expression 
Both isoflavones and resveratrol could induce APOAI gene expression in the 
presence of ERa, similar to that of 17|3-estradiol. 
Genistein induced APOAI promoter activity from 5-fold to 10-fold increase at 
concentrations 0.l|iM to 10|iM (Figure 5.3A) and the induced expression could be 
suppressed by estrogen antagonists ICI 182,870 (Figure 5.4A). In the presence of 
ERa, APOAI mRNA expression was also affected by administration of genistein. 
The expression had a 3-fold induction at 0.1 uM and 20-fold increase at luM, and 
returned to a 3-fold induction at IO|iM (figure 5.5A). 
The other two isoflavones showed a dose-dependent induction of transcriptional 
activity of APOAI in the presence of ERa. Daidzein at lOjiM exhibited 14 times of 
induction and about 5- to 6- fold increase in lower concentrations (Figure 5.3B), 
while equol displayed 7.5-fold induction at 0.1 jiM to maximum 12.5-fold at lOiiM 
(Figure 5.4C). In the pre-treatment of ICI 182,870, both isoflavone-induced promoter 
activities were suppressed (Figure 5.4B; Figure 5.4C). Both isoflavones could also 
modulate APOAI mRNA expression in the presence of ERa. Daidzein induced 
7.5-fold to 12.5-fold increase of mRNA abundance (Figure 5.5B) whereas equol 
treatment displayed a maximum 7.5-fold increase at O.S^iM and the induction was 
reduced upon increased equol treatment (Figure 5.5C). 
Resveratrol could increase APOAI promoter activity by 3-fold (Figure5.3D). 
The increases could be reduced by ICI 182, 870 (Figure 5.4D). In contrast, lOjiM 
could iip-regulate APOAI mRNA expression (Figure 5.5D) 
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5.2.2 Association of ERp and isoflavones or resveratrol on APOAI promoter 
transcription activity 
All the phytoestrogens exhibited ERp independent manner in APOAI promoter 
transcription activities. Daidzein and resveratrol showed slight increase at high 
concentrations (Figure 5.6B; Figure 5.6D), while genistein and equol showed no 
induction (Figure 5.6A; Figure 5.6C). 
5.2.3 Role of MAP Kinase, PKA and PKC in isoflavones and resveratrol in 
APOAI promoter transcription in the presence of ERa 
Upon the pretreatment of inhibitors on MAP kinase, PKA and PKC pathways, 
neither isoflavones nor resveratrol showed reduced APOAI promoter transcription 
activity in the presence of ERa (Figure 5.7). Further increases in transcription 
activities resulted when isoflavone-treated cells were pre-treated with MAP kinase 
inhibitor (Figure 5.7). 
5.2.4 Identification of promoter regions responsible for induction of APOAI 
transcription by isoflavones and resveratrol in the presence of ERa 
The transcriptionally active region responsible for APOAI expression induced 
by isoflavones and resveratrol was located at region -468 to -40. Decreased activities 
were observed when regions -468 to -243 and -243 to -40 were deleted (Figure 5.8). 
To characterize the specific regulatory region under isoflavone administration, a 
series of truncated mutants were constructed and their transcriptional activities were 
assayed. The apparent responsive elements were different under different isoflavone 
treatment. A slight decrease in activity was shown in genistein-treated cells when 
IRCE (-411 to -403) was deleted. Reduction in activity was also observed in cells 
under genistein or daidzein treatment when region -403 to -243 was deleted. 
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Treatment of daidzein or equol decreased transcriptional activities in cells 
transfected with 468/-411 and -243/-192 deletion constructs. Resveratrol treatment 
resulted in reduction of activity when region -468 to -411 was deleted (Figure 5.9). 
The region -118 to -40 might also be responsible for the phytoestrogens regulation, 
as decreased activity was displayed in cells transfected with (-118/-40) deletion 
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Figure 5.4 Effect of lel 182,870 on isoflavones and resveratrol induced APOAI 
promoter transcription activity in the presence of ERa.. HepG2 cells were seeded 
in 24 wells plate and co-transfected with ERa expression vector, APOAI-luciferase 
and control reporter was carried out for 24 hours. Cells were pre-treated with lcr 
187,870 or DMSO for 1 hour. (A) Genistein, (8) Oaidzein, (C) Equol and (0) 
Resveratrol at at OuM, I uM and 10uM were administered. Treatment with 
17f3-Estradiol was a positive control. The cells were finally lysed and dual luciferase 
activities were measured. Values are mean ±SEM, n=3. Means marked (#) are 
significantly (P<0.05) differ from same drug treatment respectively. 
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Figure 5.6 Effect of isoflavones and resveratrol on APOAI promoter 
transcription activity in the presence of ERp. HepG2 cells were seeded in 24 
wells plate and co-transfected with ERp expression vector or pCl-Neo, 
y4P(X4/-luciferase and control reporter was carried out for 24 hours. (A) Genistein, 
(B) Daidzein, (C) Equol and (D) Resveratrol at OuM, O.luM, 0.5uM, luM and I OuM 
were administered. Treatment with 17(3-Estradiol was a positive control. The cells 
were finally lysed and dual luciferase activities were measured. Values are mean 
土SEM, n=3. Means marked (*) significantly (P<0.05) differ from control (OnM) and 
same drug treatment respectively. 
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Figure 5.7 Effect of MAP Kinase, PKA and PKC inhibition on isoflavones and 
resveratrol activation of APOAI promoter transcription in the presence of ERa. 
HepG2 cells- weie traiisient transfected with ERa expression vector, 
MCM/-luciferase and control vectors. After 24 hours transfection, cells were 
pretreated with inhibitors of MAP kinase, PKA or PKC pathways for 1 hour. I uM 
isoflavones or resveratrol were then added, cells were lysed after further 24 hours 
followed by dual luciferase activities measurement. Values are mean 土SEM., n=3. 
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Figure 5.8 Identification of APOAI promoter regions involved in the 
up-regulation of expression by isoflavones and resveratrol in the presence of 
ERa. HepG2 cells were seeded in 24 well plates and co-transfected with ERa 
expression vector, truncated reporters and control plasmid. (A) Genistein, (B) 
daidzein, (C) equol and (D) resveratrol at OuM, 0.5uM, and lOuM were administered 
into the culture for 24 hours. The cells were finally lysed and dual luciferase 
activities were measured. Values are mean 土SEM, n=3. Means marked (*) are 
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Figure 5.10 Characterization of the isoflavones and resveratrol response region 
in APOAl promoter (-118/-40) in the presence of ERa. HepG2 cells were seeded 
in 24 well plates and co-transfected with ERa expression vector, truncated reporters 
and control plasmid. (A) Genistein, (B) daidzein, (C) equol and (D) resveratrol at 
OuM, 0.5uM, and lOuM were administered into the culture for 24 hours. The cells 
were finally lysed and dual luciferase activities were measured. Values are mean 
土SEM, n=3. Means marked (*) are significantly (P<0.05) different. 
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5.3 DISCUSSION 
Expression of APOAI has been associated with atherosclerosis and longevity 
(Luoma, 1997). Inside our body, numerous hormones and growth factors affect 
production of APOAI. Oral and transdermal estrogen has been found to increase 
hepatic APOAI-containing HDL production in postmenopausal women in a clinical 
trial (Walsh et al., 1994). Soy isoflavones can act as ER agonists in the regulation of 
HDL production. Resveratrol has also been demonstrated up-regulating HDL 
production in rats (Miura et al., 2003). However, how these phytoestrogens regulate 
APOAI is not well-understood. 
The present study presented a clearer picture of regulation of apoliporpeotein 
A-I. All phytoestrogens tested regulated APOAI in an ERa-dependent manner. 
Although ERp is an isoform of ERa, it failed to show any involvement in the 
regulation of APOAI transcriptional activities. As mentioned in Chapter 3, the 
lacking of AF-1 might account for it. However, whether ERa or ERa/p dimerized to 
induce the transcription was not investigated. 
Post-translational modification is not involved in APOAI regulation (Rong and 
Fisher, 2000), therefore mRNA expression can actually reflect the APOAI 
production. The mRNA expression was induced by all tested phytoestrogens in our 
‘study. The phytoestrogens might affect this gene expression in three different aspects. 
Firstly, the promoter transcription activity was mediated by ERa. The abolishment of 
the induction by ICI 182,870 supported the phytoestrogens-ERa interaction. This 
observation contradicts to a previous study (Lamon-Fava, 2000) which has reported 
that ERyiigand-mediated regulation is not involved in genistein- or estrogen-induced 
gene expression. Another study also indicates that activated ERa does not bind to the 
promoter region -256 to -41 (Harnish et al., 1996). Many binding sites for 
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transcription factors and nuclear receptors except ERE have been identified in this 
region (Widom et al., 1991); (Lamon-Fava, 2000). These studies have not addressed 
the importance of other promoter regions and downstream response elements. 
Another possible cause for the differential expression could be arisen from 
mRNA stability. It was noticed that genistein initiated a much greater fold of 
induction of mRNA expression than promoter activity. The phenomenon was not 
observed in cells treated with daidzein or equol. Since mRNA stability was not 
examined, this is purely a speculation. 
A non-genomic pathway may regulate the expression. Details about 
non-genomic role of ERa have been discussed in Chapter 3. Previous studies have 
illustrated the involvement of PKA and PKC (Zheng et al., 2000) as well as MAP 
kinase (Zheng et al., 2001) in the up-regulation of APOAI. The present study did not 
support the regulation under these pathways. However, the possibility of other 
signaling transduction pathway could not be ruled out. 
In this part of study, potential binding regions that interacted with phytoestrogen 
were partially also identified. Deletion of IRCE resulted a small decrease in 
transcriptional activity in cells under genistein treatment. Previous study has shown 
that Spl interacts with this region upon insulin treatment (Lam et al., 2003). 
Probably, the interaction of Spl to this region was facilitated by genistein. 
Previous research has shown the possibility that estrogen regulates APOAI 
through factors binding to sites A (HNF-4) and B (HNF-3) synergistically in HepG2 
cells (Harnish et al” 1996). This regulation is not a direct interaction of ERa and 
DNA, as there is no classic ERE present in this region. Electromobility shift assay 
has also reinforced this finding (Harnish et al., 1996). From the result of this study, 
involvement of HNF-4 and HNF-3 in APOAI transcription activity might occur in 
cells treated with daidzein and equol since the deletion of element A resulted a 
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decrease in transcriptional activities. 
Deletion of regions -468 to -411 and -118 to -40 resulted a decrease in 
transcriptional activities in all phytoestrogen-treated cells. Upon the analysis by 
P-Match (Dmitry Chekmenev, 2000) (a software based on combinating of pattern 
matching and weight matrix approaches for transcription factors binding sites 
searching), several CG-rich Spl binding sites were identified, such as regions -441 to 
-431 (agGGCGGggg) and -81 to-72 (agGGCCGggg). It was possible that activated 
ERa underwent conformational changes that allowed its AF-1 domain couple with 
Spl protein. This process is associated with transcription initiation (Saville et al., 
2000). Saville et al. show that ERp-Spl complex has null effect on the 
transcriptional activity. Previous results of this study has also demonstrated this null 
effect. 
Apart from the upstream region, downstream region is also participating in the 
regulation of APOAI. Upstream to the APOCIII gene, there is a downstream 
enhancer (DSE) (+8446 to +8421) that stimulates maximal levels of APOAI 
transcription in conjunction with the proximal promoter elements of APOAI 
(Ginsburg et al., 1995). Spl protein has been found to bind to this enhancer (Ivanov 
et al., 2003). Phytoestrogen might also regulate APOAI transcription through this 
region in the present study. 
In short, isoflavones and resveratrol up-regulated APOAI transcription in the 
presence of ERa. Spl binding sites on APOAI promoter may play some roles in the 
regulation. 
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C H A P T E R 6 G E N E R A L D I S C U S S I O N 
Concluded from this study, isoflavones and resveratrol could up-regulate both 
LDLR and APOAI transcription and even mRNA expression, indicating the role of 
these phytoestrogens to the cardiovascular system. 
Based in the results of this study, isoflavones up-regulates LDLR and APOAI 
transcription through ERa, thereby the expression of these two genes and even 
protein may be increased. The increased amount of LDLR and APOAI could then 
help to reduce LDL-cholesterol and increase HDL-cholesterol, and could result in 
reduction of total serum cholesterol. This illustrates the possible protective effect 
against atherosclerosis. Results of this project agree with and give a picture of 
molecular event as shown in previous studies (Anthony et al., 1998; Arliss and 
Biermann, 2002; Cassidy et al., 2003). The inducing effect at concentrations like 
0.1 uM and O.SuM demonstrated the possibility that such molecular incidents can be 
achieved by high consumption of soy products. 
Isoflavones are originally present in the form of glycosides in soy. The 
possibility of the aglycone form can affect LDLR and APOAI is rather low. Although 
a previous study has demonstrated that both glycosides and aglycones can have 
beneifical effect on lipid metabolism in rats fed cholesterol (Kawakami et al., 2005), 
the glycosides are converted to aglycones by enzymes in saliva upon ingestion 
(Allred et al,, 2001), or gut and liver during digestion (Day et al., 1998). 
Food choices in diets may affect isoflavones amount in serum and hence 
influence the expression of LDLR and APOAI. Studies have suggested that 
isoflavones are more bioavailable in food if present as aglycones, such as fermented 
soy products. Although fermentation has been reported to decrease the total amount 
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of isoflavones (Slavin et al., 1998), recovery of urinary daidzein and genistein was 
higher in subjects consuming a diet consisting of tempeh (fermented soy) compared 
to those who consumed intact soy (Hutchins et al., 1995). Therefore, consuming 
more fermented soy products may further increase serum isoflavones and thus 
increase LDLR and APOAI present in the body. 
Resveratrol, which is also a phytoestrogen like isoflavones, its effectiveness to 
induce LDLR and APOAI transcription was not as high as isoflavones in the present 
study. Only high concentration induced LDLR transcription and APOAI mRNA 
expression. Therefore, it is unlikely that the cholesterol lowering effect can be 
achieved via dietary intake. However, resveratrol may protect our cardiovascular 
system by many other ways. 
Isoflavones and resveratrol may be better alternatives in the protection of CVD 
than hormone replacement therapy (HRT). Postmenopausal women, who have sharp 
reduction of endogenous estrogen, have shown a sharp increase in serum total 
cholesterol. Receiving HRT can help to reduce the cholesterol level (Hutchins et al., 
1995; Chang et al., 1996). However, previous clinical studies has demonstrated that 
healthy postmenopausal women on HRT have an increased risk of arterial 
cardiovascular events compared with those taking placebo (Middeldorp et al., 2002). 
Other adverse effect like increased risks in breast cancer, endometrial cancer, venous 
thromboembolism were also observed (Steffen and Carries, 2000). Phytoestrogens 
have rarely been reported to exert adverse effect on animals and human. 
ERa has been demonstrated to play a very important role in the regulation of 
LDLR and APOAI. On the other hand, whether the tested phytoestrogens can affect 
the endogenous ERa expression has not been shown in this study. Studies about the 
effect of most isoflavones on ERa expression have been carried out in breast cancer 
cell line MCF-7. All the three isoflavones display down-regulation of ERa in cells 
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under long-term exposure (Wang et al., 1996; Sathyamoorthy and Wang, 1997). A 
decrease in ERa expression has also been detected in prostatic epithelium by red 
clover isoflavones (Slater et al., 2002) which includes genistein and daidzein (Howes 
et al., 2000). Since HepG2 cells do not express ERa, whether phytoestrogens will 
inhibit ERa expression may only be tested by transcription activity or mRNA 
stability in in vitro experiment, but not by its protein production (Pinzone et al., 
2004). Other cell lines may also be used for testing. As estrogen receptor regulation 
may differ in different cells, they may not reflect the actual situation happening 
inside liver. 
Apart from ERa expression, effect of endogenous estrogen on 
phytoestrogen-induced LDLR and APOAl transcription activity is also important. 
Although phytoestrogens in this study have shown to induce transcription of these 
two genes, the case which estrogen present was not tested. In the present study, it is 
noticed that physiological concentrations of isoflavones could induce a higher 
transcriptional activity than E2 at physiological concentration. As shown in previous 
studies, the binding affinity of estrogen to ER is much higher than that to 
phytoestrogens. The presence of estrogen may therefore reduce the fold of induction 
of the two genes (Mueller et al., 2004) by completing for estrogen receptor binding 
sites with phytoestrogens. 
Hepatic expression of LDLR and APOAl is the main focus of this project, but 
actually intestinal expression of APOAl has the same importance for HDL 
production (Kostner et al., 1986; Linsel-Nitschke and Tall, 2005). In the 
consideration of the cell specific promoter polymorphism of APOAl (Naganawa et 
al., 1997)，the regulation by phytoestrogens may be different. As both aglycone and 
glycoside forms of phytoestrogens are exposed to intestine, the effect of glycoside 
forms of phytoestrogens on APOAl expression warrants further investigation. 
105 
C H A P T E R 7 S U M M A R Y 
Estrogen is one of the endogenous substances which affect lipid metabolism by 
modulation of LDL receptor and apolipoprotein Al expression (Ariyo and 
Villablanca, 2002). Due to the structural similarities, many studies have illustrated 
that phytoestrogen can modulate the activity of estrogen by way of receptor binding 
(Krishnan et al., 2000). 
In the present study, physiological concentration of I7|3-estradiol was shown to 
increase LDLR and APOAI transcription in an ERa-dependent manner. Soy 
isoflavones regulated LDLR similar to 17p-estradiol, but resveratrol did not. 
Although the structure of ERp is similar to that of ERa, it did not affect the 
regulation of LDLR transcription. Other cell signaling pathways like those mediated 
by MAP kinase, PKA and PKC were not involved in the regulation of 
phytoestrogens-induced LDLR expression. ERa had also been demonstrated to be 
involved in phytoestrogens' regulations of APOAI expression. Isoflavones and 
resveratrol increased APOAI expression in the presence of ERa but not ERp. Similar 
to LDLR, pathways mediated by MAP kinase, PKA or PKC were not factors in the 
regulation. 
The response elements on the promoter of LDLR and APOAI involved in the 
regulation by phytoestrogens were also partly characterized. In LDLR, all the repeats 
located at region -202 to -127 played some roles, and R3 appeared to be the most 
important repeat in the regulation. Region -467 to -202 might also be important for 
resveratrol-induced LDLR transcription. In the promoter of APOAI, IRCE might be a 
factor in the regulation induced by genistein. Apart from this, response region -468 
to -411 and -118 to -40 also participated in the regulation of all phytoestrogens. 
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This study helped to establish a clearer picture of how phytoestrogens from soy 
and red wine might regulate some genes in lipid metabolism, by increasing 
transcription and expression of LDLR and APOAI, total cholesterol may hence be 
lowered and reduce the incidence rate of cardiovascular diseases among populations. 
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A P P E N D I X 1 A B B R E V I A T I O N S 
AF-l Activation Function-1 
AF-2 Activation Function-2 
Amp Ampiciliii 
APOAI Apolipoprotein A-1 
bp Base Pair 
BSA Bovine Serum Albumin 
cDNA Complementary Deoxyribonucleic Acid 
CVD Cardiovascular diseases 
cIATP Deoxyadenosyl Triphosphate 
DBD DNA Binding domain 
dCTP Deoxycytosiiiy 丨 Triphosphate 
dGTP Deoxyguanosinyl Triphosphate 
D M S O Dimethyl Sulfoside 
DNA Deoxyiiucleic Add 
clNTP Deoxyribonucleotide Triphosphate 
DTT Dithiotlireitol 
dTTP Deoxythymidunyl Triphosphate 
E2 17B-estradioI 
E.coli Escherichea Coli 
EDTA Ethyleiiedianiinetetraacetate 
ERE Estrogen response element 
ERs Estrogen Receptors 
E tOH Ethanol 
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FBS Fetal Bovine Serum 
FW Formula Weight 
HEPES N-2-hydroxy-ethyl-piperazine-N'-2-
Ethaiie-sulfonic acid 
HDL Hgh density lipoprotein 
kb Kilo-base 
kDa Kilo-dalton 
LB Luria-Bertani Medium 
LBD Ligand binding domain 
LCAT Lecithin:cliolesterol acyltransferase 
LDL Low density lipoproein 
L D L R Low density lipoprotein receptor 
MAP Mitogen-activated protein 
mRNA Messenger Ribonucleic Acid 
MTT 3-[4,5-DiinethyltliiazoI-2-yl]-2,5-Diphenyl 
Tetrazolium Bromide 
PBS Phosphate Buffered Saline 
PCR Polymerase chain reaction 
PKA Protein Kinase A 
PKC Protein Kinase C 
RNA Ribonucleic Acid 
RNase Ribonuclease 
rpm Revolutions per Minute 
R P M I 1640 Medium Roseweli Park Memorial Institute Tissue 
Culture Medium 1640 
RT-PCR Reverse Transcription-Polymerase Chain 
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Reaction 
SDS Sodium Dodecyl Sulfate 
Spl 
SREBP-1 Sterol regulatory element binding protein-1 
SREBP-2 Sterol regulatory element binding protein-2 
TAE Tris-acetate-EDTA 
Tris Trizma Base 
v/v Volume/ Volume 
w/v Weight/ Volume 
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A P P E N D I X 2 M A T E R I A L S A N D M E T H O D S 
2.1 C H E M I C A L S AND MATERIALS 
2.1.1 CHEMICALS 
Genistein, daidzein, equol and resveratrol, 17p-estradiol (E2) and the carrier 
solvent DMSO were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). 
The mitogen-activated protein (MAP) kinase inhibitor PD 98059, The protein kinase 
A (PKA) inhibitor myristoylated 14-22 amide and the protein kinase C (PKC) 
inhibitor bisindolylmaleimide I were obtained from Calbiochem (San Diego, CA). 
ICI 182,780 was a gift from Dr. Y. Huang (Physiology Department, the Chinese 
University of Hong Kong, HKSAR, China). All other chemicals, if not stated, were 
acquired from Sigma Chemicals. 
2.1.2 PLASMIDS 
ERp expression plasm id was obtained from Dr. Franky L.Chan (Anatomy 
Department, the Chinese University of Hong Kong, HKSAR, China). Mammalian 
expression vector pcDNA3.1+ was obtained from and Dr. Y.Y. Ho (Biochemistry 
Department, the Chinese University of Hong Kong, HKSAR, China). ERE-luciferase 
reporter plasm id C3-luc was a gift from Dr. Donald McDonnell (Duke University, 
NC, U.S.A). Reporter plain id pTA-luc was purchased from BD Biosciences Clontech 
(Mountain View, CA, USA). Ren ilia luciferase control plasmids were purchased 
from Promega Corp. (Madison, WI, USA). 
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2.2 M A M M A L I A N C E L L CULTURE 
2.2.1 MAINTENANCE OF CELLS 
The hepatocarcinoma cell line HepG2 was obtained from American Type Cell 
Collection (Rockville, MD, U.S.A.). The cells were incubated in phenol red free 
RPMI 1640 media with 2 mol/L L-glutamine (Gibco BRL, Rockville, MD, 
U.S.A.), 100,000 U/L penicillin and 100 g/L streptomycin, and 10% fetal bovine 
serum (FBS) (Gibco BRL, Rockville, MD, U.S.A.). The incubator was maintained 
at 37°C and 5% CO2 air. When cells reached about 80% confluence, the culture 
medium was removed and discarded. The cell layer was rinsed with PBS and the 
cells were trypsinized with 3 ml trypsin-EDTA for 3 minutes. The cell suspension 
was transferred to a 15-ml centrifuge tube containing 7 ml PBS and centrifuged at 
1,000 rpm at room temperature for 5 minutes. The medium was then removed 
without disrupting the cell pellet. The cells were then resiispensed in appropriate 
fresh growth medium. The cell suspension was added in aliquot into new culture 
flask. (Sub-cultivation ratio: 1:4 to 1:6) and incubated as described above. 
2.2.2 PREPARATION OF CELLS STOCK 
Semi-confluent cells in 75 cm^ flask were washed with PBS and trypsinized as 
described above. After centrifugation, the cell pellet was suspended in 450 pJ of 
RPMI supplemented with 10% v/v FBS and transferred into a 2-ml freezing tube 
containing 500 ^il of FBS and 200 |_il of DMSO. The tube was put in a isopropanol 
filled freezing pot (Nalgene, USA) and the pot was put into a -80。C freezer so that 
the cell stock was frozen at a constant rate of about 1°C /min. The frozen vial was 
transferred and stored into liquid nitrogen for permanent storage. 
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2.2.3 CELL RECOVERY FROM LIQUID NITROGEN STOCK 
The cell stock was taken out from the liquid nitrogen tank and thawed 
immediately in a 37。C water bath. To remove the DMSO, the cell stock was diluted 
into 10 ml of RPMI with 10% v/v FBS. The cell suspension was centrifuged and the 
supernatant was discarded. The cell pellet was subsequently suspended in 10 ml of 
RPMI with 10% v/v FBS, plated on a 75 cm^ culture flask and incubated as above. 
Medium was changed one day after recovery of the cells. 
2.3 MANIPULATION OF D N A 
2.3.1 ISOLATION OF H E P G 2 GENOMIC D N A 
HepG2 genomic DNA was isolated using D N e a s 严 Tissue Kit (QI AG EN Inc.) 
according to the manufacturer manual. 5x10^ cells were centrifuged for 5 min at 
lOOOrpm. The pellet of cells was then resuspended in 200|il PBS. 20j.il Proteinase K 
and 200).il Buffer AL were added to the sample, mixed thoroughly by vortexing, and 
incubated at 70°C for 10 minutes. Followed by adding 200|.il 100% ethanol, the 
sample was again thoroughly mixed by. vortexing. The resultant content was, pipetted 
into the DNeasy spin column sitting in a 2-ml collection tube. The whole set up was 
then centrifuged at 13000rpm for I minute. After discarding the flow-through and 
the collection tube, the DNeasy spin column was placed in a new collection tube, and 
next 500)0.1 ButTerAWl was added and centrifuged for 1 minute at 13000rpm. The 
flow-through and collection tube were again discarded. After the DNeasy spin 
column was placed in a new collection tube, 500fil Buffer AW2 was added and 
centrifuged for 3 minutes at full speed to dry the DNeasy membrane. The 
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flow-through and the collection tube were then discarded. The DNeasy spin column 
was finally placed in a clean 1.5-ml microcentrifuge tube, and 200|.il Buffer AE was 
added directly onto the DNeasy membrane. The set up was then incubated at room 
temperature for 1 minute and centrifuged for 1 minute at 13000ipm for elution which 
was finally repeated again. 
2.3.2 SEPARATION AND PURIFICATION OF D N A FROM AGAROSE GEL 
The agarose gels were prepared with 1.5% (w / v) agarose diss loved in IX TAE 
buffer containing 0.5 ^g/ml ethidium bromide. The volumes of DNA samples were 
adjusted to 10 to 50 |il with water or the running buffer with addition of 6X loading 
buffer to a final concentration of IX. After loading the samples into the wells of the 
gel, electrophoresis was performed at constant voltage of 90 to 125 V (10 to 14 V/ 
cm) in a gel tank containing appropriate IX TAE buffer. When electrophoresis was 
finished, DNA was visualized on a gel documentation system. 
The bands of interest were cut out and purified with the CONCERT™ Rapid 
Gel Extraction System (Gibco BRL). 30 |_LI of Gel Solubility Buffer (LI) was added 
for every 10 mg of gel in a 1.5-ml microtube at 50°C to allow complete dissolve. The 
mixture was then transferred to a cartridge on the top of a 2-ml wash tube and 
centrifuged at 13,000 rpm for I minute. The solution in the collection tube was 
discarded, 700|il Wash Buffer was added to the cartridge which was then incubated 
at room temperature for 3 minutes and centrifuged as above. The cartridge-collection 
tube assembly was centrifuged for further 1 minute to remove the residual wash 
buffer. The DNA was eluted with 40 jil of nucleus free water and collected by 
centrifugation into a new clean microtube. The eluted DNA was stored at -20°C or 
used immediately. 
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2.3.3 RESTRICTION DIGESTION OF D N A 
Restriction digestion was used to prepare DNA inserts for subcloning or for the 
confirmation of transformants, more than 5 |ig of DNA or 1 jig was used respectively. 
Plasm id DNA was mixed with restriction enzymes and the respective buffers (New 
England BioLabs) according to manufacturer's manual, all the reactions were 
incubated in a 37°C water bath for 3 hours unless instructed otherwise by the 
manufacturer. 
2.3.4 LIGATION OF D N A FRAGMENTS 
The DNA insert and vector were mixed at a 3:1 molar ratio, with 2 pi of lOx T4 
ligase buffer and 400 units of T4 ligase (New England Bio labs) (one unit being 
defined as the amount of enzyme required to give 50% ligation of Hind III fragments 
of Lambda DNA in 30 min at 16°C in 20 |LII and a 5' DNA termini concentration of 
0.12 }iM). The volume was brought up to 20 \i\ with MQ water. The reaction was 
incubated at 16。C for 16 hrs. Then the ligation product was then stored at -20°C or 
used immediately for transformation. 
2.3.5 TRANSFORMATION O F D H S A 
1 |_ig of plasm id DNA was transferred into a 1.5-ml microtube containing 100 \i\ 
of competent DH5a cells and left on ice for 30 min. The cells were placed into 42 °C 
water bath for 2min for heat shock and chilled on ice for 10 min for cold shock. The 
transformation mix was mixed with 400 jil of LB medium and incubated at 37 "C in 
a shaker for 45 min. The mixture was then centrifiiged at 3,000 rpm in a desktop 
centrifuge for 5min, and 400 of the supernatant was discarded. The pellet was 
resuspended in the residual medium and plated on plate and incubated at 37 
°C overnight. Transformants that grew on plate as single colonies were transferred 
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into 5 to 10 ml of LB。'叩 medium with toothpicks and incubated at 37 "C with 
shaking overnight. The cultures were screened by PGR with appropriate primers and 
analyzed with agarose gel electrophoresis. Transformants that scored positive with 
the PGR screening were further analyzed by restriction digest after purification of 
plasmids from DH5a cells. 
2.3.6 SMALL SCALE PURIFICATION OF PLASMIDS FROM D H 5 A 
A single colony of transformed DH5a on a LB""''' plate was inoculated into 10 
ml of L B释 medium at 3TC with shaking overnight. The overnight culture was 
transferred into a microtube and pelleted, the supernatant was discarded. Plasmids 
were purified by Wizard Plus SV Miniprep DNA Purification System (Promega Co.). 
250 |al of cell resuspension buffer was added into the microtube, followed by 
vortexing until homogenous. The suspension was then mixed with 250 jil of Cell 
Lysis Solution, gently mixed by inverting the capped tube five times. Together with 
the addition of 10 ul alkaline protease solution, the mixture was incubated at room 
temperature for 5 minutes to lyse the cells. 350 i^l Neutralization Buffer was then 
added, mixed immediately by inverting the tube five times and centrifuged at 13,000 
rpm in a desktop centrifuge for 10 minutes. The supernatant was loaded into a spin 
cartridge placed in a 2-ml wash tube and was then centrifuged at 13000rpm for 1 min. 
After disposal of the flow-through, the cartridge was placed back into the wash tube, 
750 iLiI of Wash Buffer containing ethanol was added. The set up was centrifuged at 
13000 rpm for 1 minute afterwards, the step was then repeated again with 250 |xl 
Wash Buffer. After discarding the flow-throLigh, it was centrifuged again at 13000 
rpm for 1 minute to remove residual wash buffer. Lastly, the cartridge was placed 
into a 1.5ml-recovery tube and elution was operated by adding 100 |il of 
nuclease-free water directly to the center of the spin cartridge, incubating at room 
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temperature for 1 minute and centrifuging at 丨 3000 rpm for 2 minutes. The eluted 
DNA was then stored at -20°C. 
2.4 CONSTRUCTION OF EXPRESSION AND REPORTER 
PLASMIDS 
2.4.1 CONSTRUCTION OF ESTROGEN RECEPTOR a ( E R a ) EXPRESSION 
VECTORS 
The cDNA fragment encoding the full length of ERa was amplified by PCR and 
directionally cloned into mammalian expression vector pcDNA3.1+ via BamHI and 
Xhol restriction sites, using the following oligonucleotides: sense 
[5'-TATTAGGATCCATGACCATGACCCTCCACACC-3'] and anti-sense 
[5'-TTAATCTCGAGTCAGACTGTGGCAGGGAAACC-3']. For the PCR 
amplification, 35 cycles consisting of the following steps were used: 94°C (30 sec), 
59OC (30 sec), 72。C (2 min). Amplified PCR products and pcDNA3.1+ were both 
digested with BamHI and Xhol. Then, they were ligated together. DH5a E. coli 
cells were transformed with the recombinant plasmids. Recombinant plasmid DNA 
isolated from the DH5a was analyzed by PCR, enzyme digestion and 1% agarose 
gel electrophoresis. By comparing the size of the PCR and enzyme digestion 
products, ERa complementary DMAs was successfully cloned into pcDNA3.I+. 
Finally, clones were confirmed by DNA sequencing (Marcogen Inc., Korea). 
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2.4.2 CONSTRUCTION OF REPORTER VECTORS OF LDLR PROMOTER 
AND THE RESPECTIVE MUTANTS 
The 5'flanking region of LDLR promoter and the respective truncation mutants 
were amplified by PGR and directionally cloned into firefly luciferase reporter 
pTA-luc via Mlul and Bglll restriction sites, using the common anti-sense 
oligonucleotides (5’- AATTTAGATCTCAAGGC-GACGGTCCAGCGCAA—3，）and 
different sense oligonucleotides as shown below: 
Reporter plasm id 5,flanking Sense oligonucleotides used (5, to 3，） 
region 
encoded 
pTA-LDLRfull-hic -687 to + 7 7 ^ CCGACGCGTGGATCCCACAAAACAAAAAAT 
pTA-447LDLR-\uc -447 to +77TAGGTCACGCGTGCTATTGGAGGATCTTGA 
pTA-202LDLR-\uc -202 to +77^TAAACGCGTGTTCGAAACTCCTCCTCTTGC 
pTA-I29LDLR-\uc-127 to +77GCCCACGCGTTAGAAACCTCACATTGAA 
The mutants with inactivated Repeat 1-3 either alone or in combination were 
performed with site-directed mutagenesis using pTA-202LDLR-\uc as previously 
described (Li et al., 2001). The oligonucleotides used were given below, base in 
underlined were mutated bases: 
Reporter plasm id Mutated Wildtype sequences (5’ to Mutated sequences (5’ to 
region 3，） 3，） 
pTA-Rlmut-liic Repeat 1 A A A C T C C T C C T C T T G C AAACTCtTtCTCTTGC 
pTA-R2mut-luc Repeat 2 A A A A T C A C C C C A C T G C A A A ATC ACggC ACTGC 
pTA-R3mut-liic Repeat 3 A A A C T C C T C C C C C T G C AAACTCtTtCCCCTGC 
pTA-Rl/3mLit-luc Repeat 1 Containing mutated site appeared in both R1 and R3 
and 3 regions 
In the PGR amplification, 35 cycles consisting of the following steps were used: 
94OC (30 sec), 55X (30 sec), 72X (1 min). Amplified PGR products and pTA-Iuc 
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were both digested with Mlul and Bglll. Then, they were Iigated together. DH5a 
E.coli cells were transformed with the recombinant vectors. Recombinant plasmid 
DNA isolated from the DH5a was analyzed by PGR, enzyme digestion and 1.5% 
agarose gel electrophoresis. By comparing the size of the PGR and enzyme digestion 
products, the 5，flanking region and the respective mutants were successfully cloned 
into pTA-luc. Finally, clones were confirmed by DNA sequencing (Marcogen Inc., 
Korea). 
2.4.3 CONSTRUCTION OF REPORTER VECTORS OF APOAI PROMOTER 
AND THE RESPECTIVE MUTANTS 
The 5'flanking region of APOAI promoter and the respective truncation mutants 
were amplified by PGR and directionally cloned into firefly luciferase reporter 
pTA-luc via Mlu丨 and Bglll restriction sites, using the following the common 
anti-sense oligonucleotides (5'-ACAAGATCTTTAGGGGACACCTAC-
CCGTCA-3') and different sense oligonucleotides as shown below: 
Reporter plasmid 5'flanking Sense oligonucleotides used (5' to 3') 
region 
encoded 
‘ pT\-2068APOAI-\yx<^  -2068 to +293 CCGAC^GTGGTACCTTTCTAACAGTTTTG 
^TH-468APOAI-\\.\C -468 to +293 TTCGACGCGTACTAAAGAAGAGCACTGG 
pTA-IRCE-luc -411 to +293 ATTTACGCGTAGTCTCCCTGG AATGCTG 
pTA-IRCEdel-luc-403 to +293 AAATACGCGTTGGAATGCTGGTGGTGGG 
^T\-24SAPOAI-\v\q, -243 to +293 TTTAACGCGTCTGCAAGCCTGCAGCACT 
pTA-Adel-luc -191 to +293 TAAAACGCGTCCTGCAGCCCCCGCA 
pTA-Bdel-luc -144 to +293 TTATTTACGCGTCCAGGGACAGCGCTGATC 
pTA-Cdel-luc -118 to +293 ACTGACGCGTCTTAAGTTCCACATTGCC 
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^TK-40APOAI-\WC -40 to +293 AAGGACGCGTGGCTGCAGACATAAATAG 
In the PCR amplification, 35 cycles consisting of the following steps were used: 
94^C (30 sec), 55^C (30 sec), llX (I min). Amplified PCR products and pTA-luc 
were both digested with Mini and Bglll. Then, they were ligated together. DH5a 
E.coli cells were transformed with the recombinant vectors. Recombinant plasmid 
DNA isolated from the DH5a was analyzed by PCR, enzyme digestion and 1.5% 
agarose gel electrophoresis. By comparing the size of the PCR and enzyme digestion 
products, the 5' flanking region and the respective mutants were successfully cloned 
into pTA-luc. Finally, clones were confirmed by DNA sequencing (Marcogen Inc., 
Korea). 
2.5 DETERMINATION OF PROMOTER TRANSCRTIPTIQN 
ACTIVITIES 
2.5.1 TRANSIENT TRANSFECTION OF CELLS WITH E R ALPHA 
EXPRESSION VECTOR AND PROMOTER REPORTER USING 
LIPOFECTAMINE P L U S REAGENT 
Two day before transfection, the cells were trypsinized and counted. The cells 
were plated into 24-vvell plate with density 0.7X10^ cells/wells in RPMI with 5% 
charcoal/dextran treated FBS (Hyclone). At the time of plating and during 
transfection, avoid antibiotics. 0.2 |j_g DNAs were pre-complexed with the 1.5 p-l 
PLUS reagent and diluted into 25 |j.l medium without serum. It was then incubated at 
room temperature for 15 minutes. 1 |,il of LIPOFECTAMINE Reagent was diluted 
into 25 jj.1 medium without serum in a second tube and mixed. The pre-complexed 
DNAs were combined with the diluted LIPOFECTAMINE Reagent. It was mixed 
and incubated at room temperature for 15 minutes. While complexes were forming, 
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the cells were replaced with 0.2 ml transfection medium. The 
DNAs-PLUS-LIOPFECTAMINE Reagent complexes were added into each well 
containing fresh medium on cells. The complexes were mixed gentle into the 
medium. The plate was incubated at 37 °C at 5 % CO2 for 3 hours. After 3 hours 
incubation, the volume of medium was increased to 0.75 ml with RPMI with 5% 
charcoal/dextran treated FBS. 24 hours after transfection, the cells were treated 
various concentrations of phytoestrogens and 17 -estradiol. 
2.5.2 DUAL LUCIFERASE ASSAY 
Dual Luciferase assays were preformed according to manufacturer's instruction 
(Promega Corp.). 10 fil cell lysates were mixed with 50 yd of reaction buffer 
supplemented with firefly luciferase substrate. The luciferase bioluminescence was 
measured by using a FLUOstar Galaxy plate reader. The LDLR or APOAI promoter 
transcription activities represented by firefly luciferase light units were then 
normalized with that of renilla luciferase. 
2.6 SEMI-QUANTITATIVE AND QUANTITATIVE R T - P C R 
ASSAY 
2.6.1 TRANSIENT TRANSFECTION OF CELLS WITH E R ALPHA 
EXPRESSION VECTOR USING LIPOFECTAIWINE P L U S REAGENT 
Two day before transfection, the cells were trypsinized and counted. The cells 
were plated into l2-well plate (Iwaki Corp.) with density 1.4X10^ cells/wells in 
RPMI with 5% charcoal/dextran treated FBS. The procedure of transfection was 
similar to that described in 2.5.1 except the components in the reaction mixture. 0.2 
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|.ig DNAs were pre-complexed with the 2.5 ).LI PLUS reagent and diluted into 50 )jJ 
medium without serum, while 2 |LII of LIPOFECTAMINE Reagent was diluted into 
50 fil medium without serum in a second tube and mixed. While DNAs-PLUS-
LIOPFECTAMINE Reagent complexes were forming, the cells were replaced with 
0.4 ml transfection medium. After 3 hours incubation, the volume of medium was 
increased to 1.5 ml with RPMI with 5% charcoal/dextran treated FBS. 24 hours after 
transfection, the cells were treated various concentrations of phytoestrogens and 
17 -estradiol. 
2.6.2 ISOLATION OF R N A USING T R I Z O L ® REAGENT (LIFE 
TECHNOLOGY ,USA) 
Total RNA was isolated from cells grown in 12-well plates in triplicates by 
Trizol Reagent as directed by manufacturers (Invitrogen Corp., California, USA). 
Cells were washed with cold phosphate-buffered saline (PBS) twice. 0.4 ml of 
TRIzol reagent was added in each well and the cells were lysed by gentle shaking for 
5 rnin. The homogenous samples were then transferred to a microcentrifuge tubes. 
80ul of chloroform was added. Then the samples were mixed vigorously by shaking 
for 15 s and were allowed to stand at room temperature for 3 min. The samples were 
then subjected to centrifugation at 12000 g for 15 min at 4T . Afterward, the upper 
aqueous layer was transferred to another microcentrifuge tube containing 200ul 
isopropanol. The samples were incubated at room temperature for another 10 min or 
overnight at -20 ° C and centrifuged at 12 ,000 g for 丨 5 min at 4。C. The supernatant 
was removed and the RNA pellet was washed with 350ul of 75 % ethanol by 
vortexing. Then the RNA was collected as re-pellets and air dried. 20 |il of DEPC 
water was added to re-dissolve the RNA which was then stored at -80°C. 
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2.6.3 QUANTIFICATION OF R N A 
Biophotometer (Eppendorf) was used for quantification of nucleic acid. A 1 OD 
unit at 260 nm corresponds to 50 |.ig/ml double-stranded DNA, 40 |ig/inl single 
stranded DNA and RNA, 20 }.ig/ml single-stranded oligonucleatide. The amount and 
purity of RNA were determined by measuring its absorbance at 260nm and 280nm. 
OD260 * 40 mg ml"' = Amount of RNA (mg ml"'). RNA isolated by this method 
exhibited a 260/280 ratio o f> 1.6. 
2.6.4 FIRST STRAND C D N A SYNTHESIS 
A reverse transcription-polymerase chain reaction (RT-PCR) assay was used to 
quantities LDLR, APOAl, SREBP-1, SREBP-2, Spl, ERp, GADPH and -ACTIN 
mRNA level. Sequences in appendix 2 were utilized to amplify the target cDNAs 
separately after the first strand reaction. 
A 20 |LIL reaction volume was used for 2 ug - 5 ^g of total RNA. The following 
components were added to a nuclease-free microcentrifuge tube: 
DEPC treated H2O 10-X … 
Oligo (dT),2-18(500 \ig/m\) 1 … 
RNA ^ — 
Total 11 ^^ 
The mixture was heated to 70。C for 5 minutes and chilled on ice quickly. The 
contents of the tube were collected by brief centrifugation. The following 
components were added: 
5X First-Strand Buffer 4 
DNTP (10 mM, 2.5 mM each of 1 … 
dATP, dCTP, dGTP and dTTP) 
DEPC treated H9O ^ ^ 
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Total 19.5 }_il 
The contents was mixed gently and incubated at 37°C for 5 min. 0.5 \i\ (100 
units) of M-MLV reverse transcriptase (Amersham Biosciences Ltd.) was added and 
mixed by pipetting gently up and down. The mixture was incubated at 37。C for 60 
min. The reaction was inactivated by heating at 70。C for 10 min. The cDNA was 
used as a template for amplification in PCR. 
2.6.5 SEMI-QUANTITATIVE P C R REACTIONS 
The reaction mix was prepared in the sequence depicted as follows unless 
Sterile dH20 (16-X)|il 
I OX PCR reaction buffer with 50 mM MgCl2 2 |.il 
dNTP( IOmM) 0.4 I 
Forward Primer (10 _ 0.4 |il 
Reverse Primer (10 |iM) 0.4 \i\ 
Template cDNA X 
Tag DNA polymerase (SU/ul)  
Total 20 i^l 
19 cycles for actin and 30-35 cycles for SREBP-1, SREBP-2, Spl of amplification 
were performed with a denaturation temperature 94。C for 30 s, an annealing 
temperature 60。C for 30s and extension temperature of 72 °C for 30s. After reaction, 
the mixture was analyzed by 1.5 % agarose gel electrophoresis or stored at 4 for 
short period of time or -20 for long-time storage. 
2.6.6 QUANTITATIVE P C R REACTIONS 
Real time PCR was used to quantify the relative expression level of LDLR and 
APOAI mRNA in the phytoestrogen-treated samples. The primers and the 
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FAM-labelled probes of LDLR, APOAI and internal control GADPH were all 
purchased from Applied Biosystems. The reaction mixture was prepared according 
to the manufacturer's manual. 
Sterile dH20 … 
. 1 ul 
20X LDLR or, apoAl or gapdh assay mix 
2X Taqman Universal Master Mix (with AmpErase UNG) 10 ^ il 
Template cDNA ^ 
^ . 20 … 
Total 卜 
Samples were amplified and detected using a DNA Engine OpticonTM 2 
System (MJ Research Inc.). The PGR amplification conditions were optimized 
following the manufacturer's recommendations (ABI Biosystems Inc.). The final 
thermocycling profile was 50°C for 2 min, 95。C for 10 min, and 40 cycles of 95°C 
for 15, 60°C for I min. All samples were run in triplicate or more. 
2.7 WESTERN BLOTTING 
7X10^ HepG2 cells in 60mm dish were seeded two days before transient 
transfection of ERa. After one day of transfection, the cells were replaced with fresh 
RPMl medium with 5% charcoal/dextran treated FBS, with one or two days 
incubation at 37。C. During harvesting, cells were washed twice with PBS and lysed 
by 0.5ml lysis buffer. The lysates were then subjected to cell disrupter (Branson 
Ultrasonics Corp., Danbury, CT, USA) on ice for 30s and was then centrifuged at 
13000g for 5 min. The supernatants were then transferred to a new 1.5ml microtiibes, 
they were then used immediately or stored at -80 ° C for long term storage. 
Protein concentration was determined by Bicinchonic Acid Assay (Sigma 
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Chemical Co.) with bovine serum albumin (BSA) as standard. Fifty micrograms 
protein was separated on SDS (丨OOg/丨)-PAGE and transferred to an 丨丨誦obilon 
PVDF membrane (Millipore, Bedford, MA, USA). Anti-ERa primary (Santa Cruz 
Biotechnology, Inc.)； anti-actin primary (Sigma Chemical Co.) and secondary 
antibodies conjugated with horseradish (Armoracia rusticana) peroxidase (Santa 
Cruz Biotechnology, Inc.)，were used for protein detection. An ECL Detection Kit 
(Amersham) provided the chemi-luminence substrate for horseradish peroxidase，and 
the targeted protein was visualized by autoradiography. 
2.8 STATISTICAR METHODS 
A Prism 3.0 software package (GraphPad Software, Inc., CA, U.S.A) was 
utilized for statistical analysis. The results, whenever applicable, were analyzed by 
two-tailed Student's t-test to determine if significant (P<0.05) differences observed. 
The results were expressed as means 土 SEM. 
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A P P E N D I X 3 P R I M E R L I S T S 
The primers were illustrated below: 
Spl 
Sense sequence: 5'-GAG GGT CAG TGG GCTACA- 3， 
Anti-sense sequence: 5'-GAT GAT GGG ACC AGA GTT T- 3， 
SREBP-1 
Sense sequence: 5,-TTG CCG ACC CTG GTG AGT-3’ 
Anti-sense sequence: 5'- GTG TTG CAG AAA GCG AAT GTA G-3’ 
S R E B P - 2 
Sense sequence: 5'-CAC GAC TCT GAC CAG CAC C-3, 
Anti-sense sequence: 5’-CCA GGC AGG TTT GTA GGT T-3' 
P-Actin 
Sense sequence: 5，- TCA CCC ACA CTG TGC CCA TGT ACG A-3’ 
Anti-sense sequence: 5，-CAG CGG AAC CGC TCA TTG CCAATG G-3, 
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A P P E N D I X 4 R E A G E N T S A N D B U F F E R S 
Nucleic acid electrophoresis buffers 
TAE (Tris-acetate-EDTA), SOX stock solution 
242 g/L Tris base 
57.1 ml/L glacial acetic acid 
l 00ml0 .5MEDTA(pH 8.0) 
Stored at room temperature 
TBE (Tris-borate-EDTA), lOX stock solution 
108 g/L Tris base 
55 g boric acid 
40 ml 0.5 M EDTA, pH 8.0 
6X agarose fel loading buffer 
0.25 % (w/v) bromophenol blue 
40 % (w/v) sucrose 
60 mM EDTA (pH 8.0) 
Stored at 4。C 
Medium for bacterial culture 
LB (Luria-Bertani) medium 
10 g/L bacto-tryptone 
5 g/L yeast extract 
lOg/LNaCl 
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The solution was adjusted to pH 7.0 with NaOH and the volume was made up to 1 
liter with water. The medium was sterilized by autoclave. 
Medium for cell culture 
PBS (Dulbecco's Phosphate-Buffered Saline), lOX stock solution 
115 g/LNa2HP04 
39.6 g/L NaH2P04 
58.4 g/L NaCI 
pH was adjusted to 7.5 with HCl. It was sterilized by autoclave. 
Stored at 4 
R P M I 1640 Medium 
RPMI powder (for 1 liter) 
4.78 g/L HEPES 
2 g/L NaHCOs 
The solution was adjusted to pH 7.2 with HCl and NaOH and the volume was made 
up to 1 liter with sterile water. It was then sterilized by filtration through (0.22|.im) 
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